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Bisphosphonates are chemicals 
suitable for various applications, 
mostly related to their ability to 
prevent bone resorption, and are 
used e.g. as drugs for osteoporosis 
and Paget’s disease. They possess 
also other useful characteristics, 
including effective metal chelation, 
anticancer, antiparasitic and anti-
inflammatory properties as well 
as herbicidal effects. This study 
reveals three new bisphosphonate 
related applications highlighting new 
possibilities for utilizing BPs in the 
future in waste water treatment, soil 
purification and as hydrogelators. 
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ABSTRACT 
 
Bisphosphonates (BPs), chemicals containing a P-C-P structure have been extensively 
studied since the 1960’s. As pharmaceuticals they are used for the treatment of bone related 
diseases, such as osteoporosis and Paget’s disease. Moreover, BPs possess several other 
useful characteristics, including anticancer, antiparasitic and anti-inflammatory properties 
as well as herbicidal effects. Another well known property of BPs is their ability to chelate 
metal ions which provides an opportunity for developing non-medical applications. 
Despite the great interest in BPs as pharmaceuticals, these alternatives have not been 
thoroughly examined. In the first part of this thesis, the most important physicochemical 
properties of a significant class of BPs; alkylaminoBPs, some of which are routinely used in 
the clinic, were systematically studied. Subsequently novel applications related to BPs were 
discovered and investigated.  
The first two BP applications of the thesis are related to the exploitation of the metal 
chelation properties of BPs. First, a novel method was developed by which metal ions can 
be collected from aqueous solutions into a solid BP material. A sparingly soluble BP was 
found to remove Cr3+ effectively from water solutions. The insolubility of the BP made the 
process fast and efficient since no additional precipitation step was needed. The removal of 
Cr3+ from real waste water samples of tannery industry was shown to be often over 96% 
with high capacity; in contrast for the commercially available, Diphonix® BP resin the 
removal efficiency was clearly lower. 
Secondly, a sparingly soluble alkylaminoBP with a long alkyl chain in its structure was 
shown to have an increasing effect on nickel removal from soil by a hyperaccumulative 
plant, Noccaea caerulescens in a pot experiment with metal-supplemented soil. This was due 
to the reduction of metal phytotoxicity i.e. the increase of the biomass of the BP treated 
plants in the nickel spiked soil.  
Furthermore, the first BP gelator molecules were discovered: three BP compounds were 
found to form gels in water i.e. hydrogels and one formed an organogel. Hydrogels are 
generally well applicable for biomedical and pharmaceutical purposes due to their 
biodegradability and their resemblance to natural living tissue because of their high water 
content. There are various possible applications of hydrogels e.g. in tissue engineering and 
drug delivery. The structures and the properties of the formed BP-gels were analyzed with 
several techniques, including solid state 13C and 31P CPMAS and solution state NMR 
spectroscopy, IR spectroscopy, powder X-ray diffraction, thermal analysis and scanning 
electron microscopy.   
This study reveals three new BP related applications highlighting new possibilities for 
utilizing BPs in the future in waste water treatment, soil purification and as hydrogelators.  
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TIIVISTELMÄ 
 
Bisfosfonaatit ovat P-C-P -rakenteen sisältäviä lääkeaineita, joita on tutkittu laajasti 1960-
luvulta lähtien. Niitä käytetään yleisesti luuhun liittyvien sairauksien, kuten osteoporoosin 
ja Pagetin taudin hoidossa. Lisäksi bisfosfonaateilla on useita muita hyödyllisiä 
ominaisuuksia, mukaan lukien syöpää, loistauteja ja tulehdusta estävät vaikutukset. 
Bisfosfonaatit ovat hyvin tunnettuja myös kyvystään kelatoida metalli-ioneja, mikä johtuu 
niiden kemiallisesta rakenteesta, jossa kaksi fosfonaattiryhmää tarjoaa sitoutumispaikan 
metalli-ionille. Huolimatta suuresta kiinnostuksesta bisfosfonaatteihin, niiden ei-
lääketieteellisiä sovellutuksia liittyen metalli-ionien kelatoimiseen ei ole tutkittu 
perusteellisesti. Tässä väitöskirjassa selvitettiin ensin bisfosfonaattien kliinisen käytön 
kannalta merkittävän ryhmän, aminobisfosfonaattien tärkeimpiä fysikokemiallisia 
ominaisuuksia, jonka jälkeen paneuduttiin bisfosfonaattien uusiin sovellutuksiin.  
Väitöskirjan kaksi ensimmäistä sovellutusta liittyvät bisfosfonaattien 
metalliensitomisominaisuuksiin. Ensimmäisessä sovellutuksessa kehitettiin uusi 
menetelmä metalli-ionien keräämiseen vesiliuoksista käyttäen kiinteää 
bisfosfonaattimateriaalia. Erittäin niukkaliukoisen bisfosfonaatin huomattiin poistavan 
Cr3+-ioneita tehokkaasti vesiliuoksista; nahkateollisuuden jätevesistä saatiin poistettua jopa 
yli 96 % Cr3+-ioneista, mikä oli selvästi enemmän verrattuna kaupallisesti saatavilla olevaan 
Diphonix® bisfosfonaattiresiiniin. Bisfosfonaatin liukenemattomuus teki prosessista nopean 
ja tehokkaan ylimääräisen saostusvaiheen puuttumisen ansiosta.  
Toisessa sovellutuksessa tutkittiin erittäin niukkaliukoisen alkyyliaminobisfosfonaatin 
vaikutusta hyperakkumulaattorikasvin (Noccaea caerulescens) kasvuun ja metalli-ionien 
poistoon maaperästä. Kasvihuoneessa ruukuissa suoritetussa kokeessa bisfosfonaatin 
huomattiin edistävän kasvin kasvua nikkelipitoisessa mullassa ja täten lisävään nikkelin 
poistoa maaperästä.  
Viimeisessä väitöskirjan sovellutuksessa löydettiin ensimmäiset geelejä muodostavat 
bisfosfonaatit. Kolme bisfosfonaattiyhdistettä muodostivat geelin vedessä (hydrogeeli) ja 
yksi organogeelin. Hydrogeelit ovat biohajoavia ja muistuttavat elävää kudosta suuresta 
vesisisällöstään johtuen, joten niiden käyttökohteita ovat mm. kudosten muokkaaminen ja 
lääkeaineiden kuljetus. Muodostuneiden bisfosfonaattigeelien rakenteita ja ominaisuuksia 
analysoitiin useilla menetelmillä, kuten kiinteän faasin 13C and 31P CPMAS ja liuosfaasin 
NMR spektroskopia, IR spektroskopia, jauheröntgendiffraktio, lämpöanalyysi ja 
pyyhkäisyelektronimikroskopia. 
Tämä väitöskirja esittelee kolme uutta bisfosfonaatteihin liittyvää sovellutusta, jotka 
avaavat mahdollisuudet bisfosfonaattien hyödyntämiselle tulevaisuudessa jäteveden ja 
maaperän puhdistuksessa sekä hydrogelaattoreina.  
 
Luokitus: QU 131, QU 133, QV 290, WA 690 
Yleinen Suomalainen asiasanasto: bisfosfonaatit; metallit; kromi; nikkeli; geelit; vedenpuhdistus; jätevesi; 
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AAS atomic absorption 
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 aminopurin-9-yl)-3,4-
 dihydroxyoxolan-2-yl]methyl 
 [hydroxy(phosphonooxy)pho
 sphoryl]hydrogen phosphate; 
 adenosine triphosphate 
BMD  bone mineral density 
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FTIR  Fourier transform infrared 
 spectroscopy 
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 hydroxy- 3-
 (phosphonooxy)tetrahydrofur
 an-2-yl]- 3,5,9,21-
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 2,4,6-trioxa-18-thia- 11,15-
 diaza-3,5-diphosphatricosan-
 23-oic acid 3,5-dioxide;   
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 enoxy)phosphoryl)oxy-
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 bisphosphonate 
NMR nuclear magnetic resonance 
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PEG  polyethylene glycol  
SEM scanning electron microscopy 
SPECT  single photon emission 
 computed tomography 
TGA  thermogravimetric analysis 
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 microscopy 
TNF tumor necrosis factor 
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 1 Review of the literature  
1.1 INTRODUCTION TO BISPHOSPHONATES 
Bisphosphonates (BPs) were first synthesized in the middle of the 1900th century 
(Menschutkin 1865). Their early uses were as corrosion inhibitors but they had other 
industrial applications, e.g. as complexing agents in the textile, oil and fertilizer industries. 
Initially, BPs were also used as water softeners due to their ability to inhibit calcium 
carbonate precipitation. However, nowadays their main use is in the treatment of bone 
related diseases, such as osteoporosis and Paget’s disease, since these molecules can be 
bound to the bone mineral hydroxyapatite (HA) and prevent bone resorption. (Blomen 
1995) This property of BPs has stimulated their potential uses in many skeletal related 
diseases. Thus, BPs have several clinical uses e.g. in the treatment of bone metastases and 
hypercalcemia of malignancy (Coleman 2001, Stewart 2005). However, the poor oral 
bioavailability of BPs has led to the constant search for new derivatives possessing better 
characteristics, such as higher lipophilicity. In addition, new administration routes and 
delivery systems are being investigated. Another general use of BPs has been known for 
decades i.e. they are useful in bone imaging when the BP is linked to a gamma-emitting 
technetium isotope (Subramanian et al. 1975).  
Nevertheless, the interest in BPs is not only due to their use as bone drugs, but also the 
diversity of applications in different fields in which they can be applied, i.e. both medical 
and non-medical uses. For example, BPs have been shown to exert beneficial effects on the 
cancer cells, causing an inhibition of angiogenesis as well as stimulating the immune 
system. The discovery of these characteristics has resulted in new potential applications: 
e.g. in cancer treatment (Gnant & Clézardin 2012, Morgan & Lipton 2010) as well as the 
treatment of chronic inflammatory joint diseases (Iannitti et al. 2012, Maksymowych 2002). 
Moreover, several BPs have displayed antiparasitic properties by being active inhibitors of 
parasitic protozoa, such as Trypanosoma cruzi, Trypanosoma brucei and Plasmodium falciparum 
(Ghosh et al. 2004, Rodrígues-Poveda et al. 2012). BPs also represent a new class of 
herbicides, hence, their molecular targets in plants are currently being elucidated (Chuiko 
et al. 1999, Forlani et al. 2013).  
BPs have also an impressive ability to chelate metal ions. This is attributable to the 
chemical structure of phosphonate groups which represent a binding site and it is this 
characteristic that is the basis for most of the non-medical BP applications. The BP metal 
complex formation as well as the crystal structures of BPs and their complexes have been 
extensively studied; BPs have been used, for instance, as solvent extraction reagents for 
actinide ions (Chiarizia, McAlister & Herlinger 2001, Herlinger et al. 1997). The metal 
chelation possible with BPs has also been utilized in commercial extraction 
chromatographic and ion exchange resins to separate and remove metal ions from aqueous 
solutions (Chiarizia et al. 1997, Horwitz, Chiarizia & Dietz 1997). Furthermore, different BP-
based materials have been developed, such as hybrid inorganic-organic and microporous 
materials which potentially can act as molecular sieves, catalysts etc., and thin films for 
applications in the semiconductor technology (Lohse & Sevov 1997, Neff et al. 2000).  
Based on the literature search from Chemicals Abstracts, there are more than 31 000 
publications about BPs including over 2100 patents, and even in 2013 alone about 1300 BP 
articles and patents were published. Many of the BP applications have been thoroughly 
reviewed but often those reviews have concentrated on one single application related to the 
clinical or biomedical fields. Thus, the aim of this literature review is to provide a wide 
overview of BP applications in many fields and to highlight their diversity. The huge 
amount of information about BPs is unmanageable, thus this literature review will 
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concentrate on BP applications in the most widely studied fields and especially the topics 
related to this thesis.  
1.1.1 Structure and classifications 
BPs are chemically and enzymatically stable analogues of the naturally occurring 
compound, pyrophosphate. However, instead of the P-O-P structure present in 
pyrophosphate, geminal BPs contain a P-C-P backbone (see Figure 1). The phosphonate 
bonds between the central carbon and the phosphonate groups are highly resistant to 
hydrolysis, e.g. under acidic or alkali conditions, and this means that the BP-structure is 
very stable. (Rogers 2004) The two phosphonate groups act as a “hook” with which to bind 
metal ions and their presence is essential for binding to HA (Russell 2006). There are two 
groups (R1 and R2) attached to the central carbon (geminal carbon) of the BPs, which means 
that one can create a huge number of possible BP structures. Based on a search in 
compound databank, currently over 22 000 BP structures have been synthesized, 400 of 
which are commercially available. By changing the functionalities of R1 and R2 groups, the 
properties of BPs can be greatly varied. These groups affect the compound’s affinity for 
metal ions as well as the bioactivity of the BP. For example, by changing the R group to 
hydroxyl, the compound’s affinity for metal ions and bone is predected to be enhanced. 
(Russell 2006) Nevertheless, the affinity for bone is not necessarily related to bioactivity. For 
example, the replacement of the OH-group of pamidronate and olpadronate (Figure 2) with 
a NH2 group did not affect the affinity for bone even though the antiresorptive efficacy 
declined (van Beek et al. 1996).  
 
Figure 1. The structure of pyrophosphate and the general structure of geminal bisphosphonates 
 
The BPs in medical use can be divided into two groups based on their mechanism of 
action to inhibit bone resorption: non-nitrogen-containing (NNBP) and nitrogen-containing 
(NBP) molecules. NBPs have at least one nitrogen atom in the R1 or R2 groups whereas 
NNBPs do not contain any nitrogen in their structure. NNBPs are incorporated into 
analogues of adenosine triphosphate (ATP), which induce apoptosis in osteoclasts, but 
NBPs work through different mechanism and prevent protein isoprenylation by inhibiting 
farnesyl pyrophosphate (FPP) synthase. Moreover, based on the potency of their action BPs 
can be categorized into four generations; examples being presented in Figure 2. The first-
generation BPs, like etidronate and clodronate, have simple R1 and R2 groups while the 
second-generation BPs, such as pamidronate and alendronate, contain a primary amino 
group and are 10- to 1000-fold more potent than the first-generation compounds (Figure 2). 
The third-generation BPs include a nitrogen containing heterocycle, such as in risedronate 
and zoledronate or a tertiary amino group, for example in ibandronate, which is 10 000-fold 
more potent than the first-generation BPs. (Benford et al. 1999) A novel group of BPs, with a 
nitrogen atom attached directly to the central carbon could be called the fourth-generation 
BPs. This group of BP compounds functions differently from the third generation since they 
possess herbicidal, antimicrobial, antiparasitic and antioxidant properties (Balakrishna et al. 
2011, Dąbrowska et al. 2009, Forlani et al. 2007, Ghosh et al. 2004, Kunda et al. 2012). On the 
other hand, incadronate, which structurally belongs to the fourth generation BPs, has 
antiosteoporotic activity and thus based on its function, is generally classified into the 
third-generation (Teramura et al. 2002). 
According to IUPAC, BPs in their acidic form are called bis(phosphonic acids). However, 
the use of the term “bisphosphonate” is established practice in the literature when this 
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group of compounds is generally discussed. Thus, the term “bisphosphonate” is also used 
in this thesis. Most of the BPs used as drugs are in their salt form and consequently called 
by the names of the salt forms, such as “etidronate” instead of the name of the acidic form 
“etidronic acid”. In this thesis the BPs in drug use are named as they were mentioned in the 
reference literature. 
  
 
Figure 2. Structures of the most well-known first-, second- and third-generation 
bisphosphonates as well as the general structure of the fourth-generation bisphosphonates  
1.1.2 Chemical properties and synthesis 
 
Acidity (pKa values). BPs are generally very acidic compounds, simple BPs containing four 
protons capable of dissociation. Compared to the monophosphonates, the acidic properties 
of BPs are clearly different due to the fairly strong electronic interactions between the two 
closely located phosphonate groups. The first proton of the phosphonate groups is very 
acidic, the pKa value being less than 1 and often out of the measureable pH range of the 
titration. Generally, the second pKa value is about 2.5, the third between 6 and 7, and the 
last one above 10.  If there is an alcoholic hydroxyl group attached to the central carbon, it is 
very weakly acidic and does not deprotonate below a pH value of 13. AminoBPs are mostly 
present in the zwitterionic form since the basic amino group remains protonated until the 
pH value is at least 10 to even more than 12. (Galezowska & Gumienna-Kontecka 2012, 
Matczak-Jon & Videnova-Adrabińska 2005) The presence of the amino group not only 
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introduces another protonation site into the molecule but its presence can also influence the 
other dissociation constants by increasing the acidity of the phosphonate groups. The 
increase of the acidity depends on the position of the amino group: the closer the amino 
group is to the phosphonates, the lower will be the pKa values. However, there is a 
discrepancy in the literature regarding the exact pKa values determined resulting from the 
different experimental conditions used in the measurements due to formation of weak 
complexes with alkali metal ions employed for ionic strength maintenance. (Boichenko et 
al. 2009, Kubíček et al. 2007, Matczak-Jon et al. 2006, Matczak-Jon & Videnova-Adrabińska 
2005, Zeevaart et al. 1999)  
 
Metal ion chelation (stability constants of complexes of metal ions). Generally, BPs are 
good metal ion chelators forming stable complexes with several metal ions. The stability 
constants for complex formation (log β) have mostly been measured for etidronate 
(Bouhsina et al. 2004, Cukrowski, Zeevaart & Jarvis 1999, Deluchat et al. 1997, Georgantas 
et al. 2009, Lacour et al. 1998, Nash 1997), some for alkylaminoBPs, such as pamidronate 
and alendronate (Dyba et al. 1996, Kubíček et al. 2007, Zeevaart et al. 1999) and for the 
fourth generation aminoBPs (Matczak-Jon et al. 2002, Matczak-Jon et al. 2006, Matczak-Jon 
et al. 2010) as well as for some others, such as the phenyl ring containing BPs (Gumienna-
Kontecka et al. 2002a, Gumienna-Kontecka et al. 2002b). However, due to the use of 
different determination methods and the variable ionic strengths, the stability constants in 
the literature are seldom comparable with each other. Moreover, many of the studies have 
been performed in the presence of K+/Na+ ions, which also become complexed with 
bisphosphonates, thus disturbing the determination of exact complex stability constants 
(Kubíček et al. 2007). In addition, the values of stability constants for protonated complexes 
depend on the values of protonation constants of basic sites in the ligand or for 
hydroxocomplexes on the values of protonation, deprotonation or substitution constants to 
form hydroxospecies. As an example, some stability constants of etidronate, pamidronate 
and alendronate with different metal ions are presented in Table 1; not to be compared with 
each other, but rather to indicate generally the stability of BP metal complexes. 
 
Table 1. Stability constants (log β) of MH2L complexes of etidronate, pamidronate and 
alendronate with different metal cations 
 
log β 
 Cu2+ Ni2+ Cd2+ Zn2+ Fe2+ Cr3+ Al3+ 
Etidronate 20.1a 20.3a 20.7a 20.2a 21.0a 28.9b 19.1b 
Pamidronate 29.53c   28.24c    
Alendronate 30.20c   28.85c    
a) (Deluchat et al. 1997) b) (Lacour et al. 1998) c) (Kubíček et al. 2007) 
 
Synthesis. Several methods for the synthesis of BPs have been applied depending on the 
structure of the R1 and R2 groups and the possible ester functions of the phosphorus ends. 
Only a few of the basic methods for preparing BPs are presented here.  
The first method to synthesize 1-hydroxy-1,1-bisphosphonates is based on the reaction of 
a carboxylic acid, acid halide or tertiary amide in the presence of phosphorus acid and 
phosphorus trichloride followed by hydrolysis (Scheme 1, A). The best solvent for the 
synthesis was found to be methanesulfonic acid which keeps the reaction in a fluid state, 
thus allowing the complete conversion of the carboxylic acids and it achieves excellent 
yields. (Kieczykowski et al. 1995) By using a cyanide compound as the starting material in 
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this method, an amino group can be obtained as the second substituent in the central 
carbon (Scheme 1, B). However, in this case benzenesulfonic acid has to be used as the 
solvent. (Szajnman et al. 2005) Another one-pot method for preparing 1-hydroxy-1,1-
bisphosphonates is to utilize the Michaelis-Arbuzov method (Kosolapoff 1953) which is 
conducted via the reaction of acyl halide, trialkylphosphite and dialkylphosphite (Scheme 
2). This method makes it possible to prepare BP esters with either symmetrical or 
unsymmetrical ester functions. (Lecouvey & Leroux 2000, Tromelin, El Manouni D. & 
Burgada 1986) The most recently published method for the synthesis of 1-hydroxy-1,1-
bisphosphonates involves catecholborane as an activator for the carboxylic acid after which 
tris(trimethylsilyl)phosphite is added and the reaction is completed by adding methanol 
(Sheme 3). The reaction was shown to be suitable for a wide range of carboxylic acids 
containing free primary or secondary amines, tertiary amines, free hydroxyl groups, 
multiple bonds etc. (Egorov et al. 2011) 
 
 
Scheme 1. A common method to synthesize 1-hydroxy-1,1-bisphosphonates (Kieczykowski et 
al. 1995) 
 
 
Scheme 2. Synthesis of 1-hydroxy-1,1-bisphonates using trialkyl phosphite and dialkylphosphite 
(Lecouvey & Leroux 2000, Tromelin, El Manouni D. & Burgada 1986) 
 
 
Scheme 3. Synthesis of 1-hydroxy-1,1-bisphonates utilizing catecholborane activation of the 
carboxylic acid (Egorov et al. 2011) 
 
A common strategy to prepare BPs is to use Michaelis-Arbuzov method involving the 
reaction between an alkylhalogen, such as dichloromethane or dibromomethane, and 
trialkyl phosphite (Scheme 4). The hydrogen in the central carbon can be replaced by 
another substituent by using a base and reacting it with a suitable halogenated compound 
after which the ester functions can be removed by hydrolysis. (Abdou & Shaddy 2009, 
Siddall & Prohaska 1965, Vepsäläinen, Nupponen & Pohjala 1991) The fourth generation 
aminomethyleneBPs can be synthesized by a method involving orthoformate (Scheme 5). 
The reaction typically begins with the nucleophilic addition of an amine to the triethyl 
orthoformate resulting in two types of imine intermediates which readily undergo 
nucleophilic addition of the dialkyl phosphite. (Dąbrowska et al. 2009)  
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Scheme 4.  A general reaction for bisphosphonate synthesis (Abdou & Shaddy 2009, Siddall & 
Prohaska 1965, Vepsäläinen, Nupponen & Pohjala 1991) 
 
 
Scheme 5. Synthesis of fourth generation bisphosphonates (Dąbrowska et al. 2009) 
1.1.3 Characterization and analysis 
BPs are most commonly characterized by nuclear magnetic resonance (NMR) spectroscopy 
whereas Fourier transform infrared (FTIR) spectroscopy is mainly used as a supplemental 
method. Elemental analysis and thermogravimetric analysis (TGA) have also been used for 
the characterization. Analysis of BPs can be divided into two major groups: quality control 
of pharmaceuticals containing BPs and the analysis of biological materials, such as urine 
and blood. There is a wide variety of analytical methods for BP determination each of 
which have their demands e.g. concerning sample preparation, sensitivity and selectivity. 
(Zacharis & Tzanavaras 2008) The most widely used characterization and analysis methods 
are described briefly below. 
 
NMR spectroscopy. 1H, 13C and 31P NMR spectroscopies are useful methods for analyzing 
the chemical composition of BPs in liquid and solid states. Liquid state NMR is more 
commonly used for the identification of synthesis products, while solid state measurements 
are usually utilized only for poorly soluble compounds. The presence of phosphorus atoms 
in BP structure makes the utilization of 31P NMR highly beneficial. Generally, the 
phosphorus atoms of a BP are symmetrical giving rise to a single signal around 20 ppm in 
the 1H decoupled 31P spectrum. However, the presence of different ester functions at each of 
the phosphonate groups lead to asymmetry in the phosphorus atoms and this leads to the 
appearance of two doublet signals in the 31P spectrum. Thus, the simplicity of 31P spectra of 
BPs compared to the 1H and 13C spectra is often very useful in spectrum interpretation. 
Moreover, quantification methods of BPs based on 1H (Chou, Shimmon & Ben-Nissan 2009) 
and 31P (Lenevich & Distefano 2011) NMR have been reported holding the advantage of 
simple sample preparation and non-destructivity. However, the NMR methods are rather 
insensitive, e.g. the 31P NMR method described by Lenevich and Distefano is only capable 
of determining concentrations above 200 μM (Lenevich & Distefano 2011). 
 
IR spectroscopy. In addition to characterization, IR can be very useful method for the 
investigation of the protonation state of the phosphonate groups. The most important 
characteristics visible in the IR spectroscopy of BPs are the stretching and bending modes of 
P=O, P-O(H) and P-O- groups giving rise to the bands in the fingerprint region below 1320 
cm-1. (Zenobi et al. 2008) The band attributable the P=O stretch generally appears at 1220-
1150 cm-1 (Pretsch, Bühlmann & Affolter 2000). Accordingly, for clodronate isopropyl esters 
the P=O stretch band was observed at around 1230 cm-1 (Kivikoski et al. 1993) and for Mg, 
Ba, Ca and Sr complexes of clodronate diethyl esters at 1260-1220 cm-1 (Kontturi et al. 2002). 
The P-O asymmetric and symmetric stretching vibrations generally give rise to the bends at 
1050-970 cm-1 (Pretsch, Bühlmann & Affolter 2000). For example, the asymmetric bends for 
etidronate were situated at 1146-1075 cm-1 while the symmetric ones were at 1057-986 cm-1 
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(Zenobi et al. 2008). Additionally the asymmetric and symmetric P-C-P vibrations can be 
observed at 800-700 cm-1 but the intensities of the absorption signals can vary widely 
(Kivikoski et al. 1993, Kontturi et al. 2002, Pretsch, Bühlmann & Affolter 2000). 
 
Ultraviolet-visible light (UV-Vis) spectrophotometry. Generally, the use of UV-Vis 
spectrophotometric assays is simple, rapid, cost-effective and the instrumentation is widely 
available (Walash et al. 2009, Zacharis & Tzanavaras 2008). However, the direct 
spectrophotometric determination of BPs is not possible because of the lack of characteristic 
absorption or fluorescent spectra in UV or visible region (Koba, Koba & Przyborowski 
2008). Instead, indirect spectrophotometric methods based on either total phosphorus 
determination or complexing and derivatization reactions prior to spectrophotometric 
analysis can be used.  
BPs can be quantitatively converted to orthophosphate to exploit the spectrophotometric 
methods developed for the determination of orthophosphate, when no other phosphorus 
containing compounds exist in the sample solution (Walash et al. 2009). Most of the popular 
spectrophotometric procedures are based on the reaction of orthophosphate with 
molybdate, and vanadate or antimonate in an acidic medium to form molybdophosphoric 
acid complexes (APHA 2005, Jastrzębska 2009, Motomizu & Li 2005, O’Toole et al. 2007, 
Walash et al. 2009). Nevertheless, only limited knowledge is available about the suitability 
of these methods for the determination of BPs. 
Few nondestructive methods based on either the metal complex formation or 
derivatization of BPs have been reported. The formation of highly stable metal BP 
complexes with a reporter group giving rise to a spectroscopic change observable by UV-
Vis or fluorescence spectroscopies can be used as an analytical method for BP detection 
(Gaidamauskas et al. 2009). Alendronate, clodronate, etidronate and risedronate (Figure 1) 
have been determined by UV-spectrophotometric methods after complex formation with 
Fe3+ and Cu2+ ions (Koba, Koba & Przyborowski 2008, Kuljanin et al. 2002, Walash et al. 
2008). In addition, the derivatization of the primary amino group with a suitable UV 
chromophore has been described for the quantification of alendronate (Koba, Koba & 
Przyborowski 2008, Taha & Youssef 2003, Walash et al. 2012).  
 
Chromatographic analysis. The direct chromatographic analysis of BPs is complicated due 
to the lack of a suitable UV chromophore for conventional high-performance liquid 
chromatographic analysis (HPLC) and insufficient volatility for gas chromatographic 
analysis (Peng & Dansereau 2001, Zacharis & Tzanavaras 2008). However, several 
chromatographic methods have been applied for the determination of BPs, e.g. reversed-
phase and ion-pair HPLC, ion chromatography and gas chromatography, the majority of 
which employ pre- or post-column derivatization reactions (Peng & Dansereau 2001, 
Sparidans & den Hartigh 1999, Walash et al. 2008, Zacharis & Tzanavaras 2008). However, 
evaporative light-scattering detection does not require derivatization of BPs; an example is 
its use coupled with the ion-pair HPLC (Niemi et al. 1997). In addition to chromatographic 
analysis, derivatization has been undertaken prior to capillary electrophoresis and mass 
spectrometry (Peng & Dansereau 2001, Sparidans & den Hartigh 1999, Zacharis & 
Tzanavaras 2008). Despite the advantage of the sensitivity offered by these methods, there 
are also drawbacks e.g. time consumption, high price, poor sampling rate and the 
requirement for highly sophisticated instrumentation (Walash et al. 2008, Walash et al. 
2009). 
1.1.4 Bisphosphonate derivatives  
In order to improve the poor oral bioavailability as well as the other characteristics of BPs, 
many BP derivatives have been synthesized over the years. Generally, the substituents at 
the central carbon are probably the most common site of variation for the modification of 
BP structures but sometimes this approach is not possible. One way to improve the 
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lipophilicity of BPs is to use the prodrug approach by adding ester functions to the 
phosphonic acid groups. Clodronate is an example of a BP where the promoieties can only 
be linked to the phosphorus atoms. The derivatives of clodronate have been investigated 
systematically and the simple esters were found to be chemically and enzymatically stable. 
Thus, these derivatives did not release the parent drug and could not be considered as 
prodrugs. (Vepsäläinen 2002) However, clodronic acid dianhydrides as well as 
acyloxyalkyl esters were found to be bioreversible prodrugs of clodronate (Figure 3) (Niemi 
et al. 1999). In addition, the hydroxyl group substituent in the central carbon (e.g. in 
etidronate) can be derivatized with an ester function to increase the lipophilicity of the 
compound (Figure 3). However, the derivatization of the hindered tertiary hydroxyl group 
at the central carbon is not very convenient, and the rearrangement of the P-C(OH)-P 
structure to a P-C-O-P structure occurs easily with the fully esterified BP. (Turhanen & 
Vepsäläinen 2005) One of the proposed prodrug approaches to enhance the bioavailability 
of BPs has been to convert them to peptidyl prodrugs and target the carrier system to the 
intestine (Figure 3). Oral administration of these prodrugs in rats resulted in a 3-fold 
increase of drug absorption. (Ezra et al. 2000) The use of BP derivatives in other delivery 
systems has also been investigated. For instance, alendronate was derivatized with 
polyethylene glycol (PEG) to reduce the adverse effects (Figure 3). The PEG-alendronate 
could be delivered pulmonary in rats with unaltered therapeutical effects as compared to 
alendronate, and the pulmonary mucosal damage caused by alendronate decreased. 
(Katsumi et al. 2011)  
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Figure 3. Examples of BP derivatives (structures drawn in the acidic form for clarification) (Ezra 
et al. 2000, Hochdörffer et al. 2012, Katsumi et al. 2011, Niemi et al. 1999, Reinholz et al. 
2010, Turhanen & Vepsäläinen 2005) 
 
One reason for derivatizing BPs is to achieve bone targeting for the delivery of other 
drugs. Conjugating BPs to other drugs has been shown to be one way to enhance and 
prolong the drug effects in bone and to reduce adverse effects resulting from their 
distribution to non-target tissues. On the other hand, the conjugation of BPs can reduce the 
cellular uptake of the drug because of the hydrophilicity of BPs and the increase in the 
molecular weight. (Giger, Castagner & Leroux 2013) One promising possibility for the 
treatment of bone metastases could be the combination of BPs with other chemotherapeutic 
drugs to improve the therapeutic outcome. Recently, Hochdörffer et al. designed novel 
water-soluble prodrugs in which the BP part acted as the bone targeting moiety and 
doxorubicin as the anticancer agent (Figure 3). The parent drug was successfully released 
either at an acidic pH or enzymatically, and high affinity for HA was demonstrated. 
(Hochdörffer et al. 2012) Furthermore, a cytotoxin, arabinocytidine-5´-phosphate linked to 
etidronate forming a nucleotide-BP conjugate (Figure 3) was shown to reduce the incidence 
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of bone metastases to 40% in mice as compared to the 90% incidence after placebo or the 
100% incidence after zoledronate treatment. This prodrug also increased the bone volume 
as well as the bone mineral density (BMD). (Reinholz et al. 2010)  
1.1.5 The mechanism of action in body 
Despite the use of BPs in the clinic, their mechanism of action remained somewhat unclear 
for a long time before it was elucidated during the last 10 years. Because of their three-
dimensional structure, BPs have the ability to chelate divalent metal ions like Ca2+ (Jung, 
Bisaz & Fleisch 1973). This is the reason why BPs bind so well to the bone mineral HA 
which consists mostly of calcium phosphates, and leave the circulation rapidly and target 
the sites of active bone remodeling, especially the areas of bone resorption (Chen et al. 2002, 
Cocquyt et al. 1999, Cremers et al. 2002). During bone resorption, BPs are released from the 
bone mineral surface because of the acidic environment of the resorption lacuna and the 
compounds are taken up into osteoclasts by endocytosis (Coxon et al. 2008). BPs inhibit 
bone resorption by reducing the activity of bone-resorbing osteoclasts or by increasing the 
rate of their apoptosis (Rogers 2004). In addition, BPs enhance the viability of osteoblasts, 
which are responsible for bone formation, as well as osteocytes, mature osteoblasts, 
responsible for the response of the skeleton to systemic and mechanical stimuli (Bellido & 
Plotkin 2011).  
Simple BPs such as clodronate, etidronate and tiludronate are metabolized to toxic 
analogs of ATP and are taken up by osteoclasts (Frith et al. 1997, Klein, Martin & Satre 1988, 
Rogers et al. 1994). Because of their non-hydrolysable nature, their accumulation within 
cells is probably able to inhibit many intracellular metabolic enzymes crucial for cell 
function and this can trigger apoptosis (Auriola et al. 1997, Benford et al. 1999, Frith et al. 
1997, Frith et al. 2001). On the other hand, the NBPs are not metabolized but they inhibit 
FPP synthase (FPPS) which is a key enzyme in the mevalonate pathway (Figure 4). The 
mevalonate pathway produces cholesterol and isoprenoid lipids like FPP and 
geranylgeranyl pyrophosphate (GGPP), which are needed for posttranslational 
modification, i.e. prenylation, of small GTPase signaling proteins, including Ras, Rho and 
Rac. (Rogers 2004) FPPS is the major target of NBPs, although some NBPs are also much 
weaker inhibitors of other enzymes in the mevalonate pathway, such as GGPP synthase or 
squalene synthase. Since they inhibit FPPS, NBPs prevent the synthesis of FPP directly and 
the synthesis of GGPP indirectly. The loss of FPP and GGPP leads to the prevention of 
prenylation; farnesylation and geranylgeranylation of small GTPases. Prenylated small 
GTPases are important signaling proteins regulating many cell processes vital for 
osteoclasts. Thus, loss of prenylation of small GTPases in osteoclasts induced by NBPs leads 
to a loss of bone-resorptive activity and osteoclast apoptosis. In addition, the inhibition of 
FPPS leads to the accumulation of isopentenyl pyrophosphate (IPP), a metabolite upstream 
from FPP synthase in mevalonate pathway (Figure 4). This accumulation causes the 
production of new metabolite ApppI, which also induces osteoclast apoptosis. (Rogers et al. 
2011) 
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Figure 4. The mevalonate pathway and its inhibition by nitrogen-containing bisphosphonates 
(Galezowska & Gumienna-Kontecka 2012, Giger, Castagner & Leroux 2013) 
 
The action of BPs on osteoblastic cells differs from their action on osteoclasts in various 
ways (Bellido & Plotkin 2011). Firstly, Plotkin et al. proved that BPs prevent the apoptosis of 
osteoblasts and osteocytes both in vitro and in vivo at concentrations several orders of 
magnitude lower than those needed for the inhibition of osteoclast activity. Secondly, all 
BPs (NNBPs and NBPs) irrespective of whether they can induce osteoclast apoptosis or not, 
seem to act with the same mechanism related to the activation of the extracellular signal-
regulated kinases (ERKs). ERK-activity is required for the prevention of apoptosis, and BPs 
activate ERKs by increasing the phosphorylation of these enzymes in osteoblasts. (Plotkin 
et al. 1999, Plotkin, Manolagas & Bellido 2006) 
1.1.6 Pharmacokinetics 
The oral absorption of BPs is very low, only approximately 1-3%, most likely because of 
their hydrophilicity which is preventing transcellular transport across the epithelial 
barriers. For this reason, BPs have to be absorbed via paracellular transport in the 
circulation. BPs are partly ionized and negatively charged at physiological pH (6-8) such as 
that in the small intestine. Furthermore, they have rather large molecular sizes, and this 
hinders paracellular transport since the brush-border membrane is also negatively charged. 
In addition, complexation between BPs and Ca2+ or other divalent cations in the system 
might reduce the extent of absorption. However, at higher dosages, a lower fraction of BPs 
is complexed with Ca2+, which increases drug bioavailability. On the other hand, high doses 
of BPs may impair the normal mineralization of the bone. (Cremers & Papapoulos 2011, 
Giger, Castagner & Leroux 2013, Lin 1996) 
The distribution of BPs has mostly been studied with 14C- and 99mTc-labeled BPs (Kumar 
et al. 2006, Weiss et al. 2008). In the 1990’s it was shown that BPs are primarily taken up by 
bone while much of that not taken up is excreted by the kidneys into the urine. 
Nonetheless, in mice some of the BPs were taken up by the soft tissues, like liver, kidney 
and spleen. (Mönkkönen, Koponen & Ylitalo 1990) The elimination of BPs from plasma is 
very rapid: after intravenous (i.v.) administration to animals and humans the half-life is 
around 1-2 h due to renal excretion and bone uptake (Lin 1996). The exact mechanism to 
explain how BPs are transferred to bone from the circulation is not known, but it is believed 
that BPs enter the extracellular matrix of the bone via paracellular transport and bind there 
to free HA (Cremers & Papapoulos 2011). The uptake of BPs in the skeleton depends on 
renal function, rate of bone turnover and the binding affinity of the BP. The distribution in 
bone is not homogenous, i.e. BPs target to the sites of bone remodeling. (Cremers, Pillai & 
Papapoulos 2005)  
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After becoming attached to the bone, BPs are liberated from the HA during bone 
resorption. When desorbed from HA, BPs can be taken up by osteoclasts or again by the 
bone, or they can be released back to the circulation. The BP embedded in bone is released 
only during resorption and therefore the half-life of BPs in bone depends largely on the rate 
of bone turnover. (Cremers & Papapoulos 2011) The terminal elimination of BPs from 
skeleton can be very slow, e.g. for alendronate in postmenopausal women suffering from 
osteoporosis it is approximately 10 years (Khan et al. 1997). Nevertheless, the skeletal 
elimination half-lives achieved in the experiments can vary extensively depending on the 
design of the experiment, follow-up time and the analytical and pharmacokinetic methods 
being used (Cremers, Pillai & Papapoulos 2005). BPs are metabolically very stable and only 
a few BPs (NNBPs etidronate and clodronate) are known to be metabolized to cytotoxic 
ATP analogues. Other BPs are mainly excreted intact via the kidney, though a very small 
amount may be eliminated in the bile. (Cremers & Papapoulos 2011)  
1.1.7 Administration and adverse drug events  
BPs are currently administered either orally or intravenously. Because of the low 
bioavailability, oral dosing of BP-drugs is very strict: taking the tablets on an empty 
stomach with a small amount of water and no other food or beverages, and remaining 
upright for 30 min (Cramer et al. 2007). In addition, orally administered BPs can evoke 
gastrointestinal distress like esophagitis, mucositis, nausea, vomiting and diarrhea. For this 
reason i.v. infusions are another popular option for BP dosing. The i.v. administration is 
less frequent, e.g. once a month instead of the daily oral administration, which often results 
in better patient compliance. (Conte & Guarneri 2004) One common adverse effect, an acute 
phase reaction to NBPs, involves fever and other flu-like symptoms occurring soon after the 
first i.v. administration of the drug. The reason for this effect appears to be the 
accumulation of IPP caused by the inhibition of FPPS by NBPs. (Rogers et al. 2011) As far as 
the i.v. administration is concerned, there is a small risk of decreased renal function, but 
this remains minimal when BPs are used at the recommended doses and infusion times. 
Nevertheless, serum creatine monitoring is suggested when using BPs intravenously. 
(Conte & Guarneri 2004) In addition to oral and i.v. administration, other administration 
routes, such as transdermal, intranasal and pulmonary are under investigation as ways to 
improve the bioavailability as well as enhancing patient compliance and safety (Ezra & 
Golomb 2000, Katsumi et al. 2010, Kusamori et al. 2010).  
In addition to the gastrointestinal side effects and the flu-like symptoms or renal failure, 
which can often be avoided by changing dosing or administration routes, another 
established adverse effect of BPs is osteonecrosis of the jaw. The main clinical feature of this 
condition is an area of exposed bone in mandible, maxilla or palate that fails to heal over a 
period of 6 to 8 weeks. During the 21st century, there have been many cases of 
osteonecrosis of the jaw as have the numbers of publications examining this topic. The 
incidences seem to be more common for i.v. than oral BP application and are often related 
to oncological patients treated with high doses of i.v. BPs. (Kühl et al. 2012, Pazianas et al. 
2007) Thus, in osteoporotic patients, the estimated incidence is 1 case per 100 000 persons 
while in oncology patients, it is estimated to be much higher, already 1-12% (Khan et al. 
2009). Tooth removal or periodontal disease is strongly associated with the appearance of 
the condition but the pathogenesis is still unclear though several mechanisms have been 
proposed (Rizzoli et al. 2008). 
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1.2 MEDICAL APPLICATIONS OF BISPHOSPHONATES 
The current clinical use of BPs is displayed in Table 2. The information about the drugs in 
the market shown in the table was obtained from the U.S. Food and Drug Administration 
(FDA) and contains only the drugs that are approved for use in the USA. However, the use 
of BPs is somewhat similar in Europe with some exceptions. Clodronate, for example, is 
commonly used outside USA for the treatment of hypercalcemia and osteolytic bone 
metastases but it is not approved in the USA. Similarly, ibandronate is licensed in Europe 
for the treatment of bone metastasis but in USA only for osteoporosis. (Coleman 2001, 
Purohit et al. 1995) In addition, olpadronate, neridronate and minodronate have been 
registered to a limited extent for clinical applications in some countries (Russell 2011). 
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1.2.1 Bisphosphonates in the treatment of bone diseases  
 
Osteoporosis. BPs are the most widely used drugs for the treatment of osteoporosis, which 
is considered as a major health problem and is most common in postmenopausal women. It 
is an asymptomatic condition with a reduction in bone mass that leads to an increased 
susceptibility to fractures. (Chapurlat & Delmas 2006) In osteoporosis, the balance between 
bone resorption and bone formation is disturbed in favor of resorption, which is the reason 
for increased bone loss (Cremers, Pillai & Papapoulos 2005). BPs are effective in reducing 
bone turnover and increasing the BMD, hence they reduce the risk of vertebral fractures. 
Etidronate was the first BP licensed for the treatment of osteoporosis at the end of the 
1980’s. Subsequently alendronate, ibandronate, risedronate and zoledronic acid have 
become generally used BPs in the clinic. (Eastell et al. 2011) Because of the bioavailability 
and affinity for bone, some of the BPs are more effective in bone than the others (Le Goff et 
al. 2010). The administration route also affects the rapidity and the magnitude of the 
response, as far as bone turnover is concerned (Eastell et al. 2011). The efficacy of different 
BPs in the treatment of osteoporosis has been widely investigated with variable 
experimental settings and in many clinical trials. These studies have also been exhaustively 
reviewed (Bilezikian 2009, Chapurlat & Delmas 2006, Delmas 2005, Eastell et al. 2011, Le 
Goff et al. 2010), therefore, only a few examples will be mentioned here. Recently, the 
research of BPs in the treatment of osteoporosis has focused on safety in addition to the 
efficacy. 
The long-term effects of alendronate were studied in postmenopausal women in a trial 
lasting ten years, in which it was shown that the daily treatment by alendronate was 
associated with sustained therapeutic effects on bone density and remodeling. In addition, 
alendronate was well tolerated and there were no signs of the diminishing of its 
antifracture efficacy but the discontinuation in the treatment resulted in the reduction of its 
effects. However, after terminating the alendronate treatment, there was little loss of BMD 
as was the increase in bone turnover, which indicated that alendronate had long-lasting 
effects on bone. (Bone et al. 2004) Similar results were obtained by Ensrud et al. in another 
long-term clinical trial (Ensrud et al. 2004). Risedronate has been investigated for the long-
term safety and efficacy by Mellström et al. in a clinical trial lasting seven years, in which 
women with postmenopausal osteoporosis received 5 mg of risedronate or placebo daily 
for five years, and then both groups were given risedronate for the last two years. Although 
there was no placebo arm in the last two years’ extension part, the data did not reveal any 
indication of loss of antifracture efficacy of risedronate over seven years and the drug also 
seemed to be well tolerated. (Mellström et al. 2004) Zoledronic acid is the most recent BP 
approved for the treatment of osteoporosis by FDA in the USA in 2007 (Bilezikian 2009). It 
was proven to achieve as good results as the other, daily orally administered BPs when 
given as intermittent infusions once a year (Black et al. 2007, Reid et al. 2002). Zoledronic 
acid (i.v. once-yearly) was also found to be superior to daily oral risedronate for the 
treatment of glucocorticoid-induced osteoporosis in a clinical trial (Devogelaer et al. 2013). 
The clear benefits of zoledronic acid compared to other BPs are its cost-effectiveness 
(Fardellone et al. 2010) and good patient compliance.  
 
Paget’s disease. Paget’s disease has a great importance with respect to the history of the 
BPs, since almost all of the well-known BPs have first been studied in Paget’s disease, 
revealing the principles about their actions in bone. Paget’s disease is characterized by 
regions of increased bone turnover which is causing symptoms, such as bone pain, 
fractures, and skeletal deformities. The numbers of osteoclasts and osteoblasts are 
increased, the first causing bone resorption, and the latter formation of bone with poor 
quality, as well as bone expansion. (Reid & Hosking 2011) Paget’s disease is rare before the 
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age of 55 and mostly affects people of European descent. It is often asymptomatic and 
about 40% of patients have symptoms at the time of diagnosis. (Ralston 2013)  
BPs are very optimal for the treatment of Paget’s disease due to their selective delivery to 
the affected tissues, i.e. to the sites of increased bone turnover. Due to their great ability to 
normalize the turnover over the long term, they are the primary drugs used for the 
treatment of Paget’s disease. Similarly to its use in osteoporosis, prescribing zoledronic acid 
has become a very popular option for the treatment of Paget’s disease because of its high 
efficiency, easy usage and low cost. (Reid & Hosking 2011) Reid et al. compared daily oral 
dosing of risedronate with a single injection of zoledronic acid over time periods up to six 
months. Zoledronic acid was not only equivalent but to some extent even superior to 
risedronate i.e. it was better than the drug considered as standard therapy. (Reid et al. 2005) 
In addition, a single injection of zoledronic acid was found to maintain its effect on bone 
turnover for over 24 months whereas daily oral risedronate administered for 60 days was 
not that effective post-treatment (Hosking et al. 2007). 
 
Osteolytic bone disease of multiple myeloma. BPs represent the standard care for 
osteolytic bone disease related to multiple myeloma which is a malignant, neoplastic 
proliferation of plasma cells, representing about 10% of blood cancers, generally affecting 
older adults. Osteolytic bone disease develops in the majority of the multiple myeloma 
patients resulting from the increase of osteoclast function, mediated by the release of 
osteoclast-stimulating factors by myeloma cells, and the inhibition of bone formation by 
osteoblasts. This can cause skeletal related events, such as bone pain and fractures. (Raje & 
Roodman 2011, Terpos et al. 2009) The first BPs shown to reduce bone pain were clodronate 
(Lahtinen et al. 1992) and pamidronate (Berenson et al. 1996) and later zoledronic acid 
(Rosen et al. 2001). Zoledronic acid is nowadays most frequently used for the treatment of 
the skeletal related events (Terpos et al. 2009) and, furthermore, it has been proven to have 
potential antimyeloma effects (Morgan et al. 2010). The studies concerning the use of BPs in 
multiple myeloma have been thoroughly reviewed by Mhaskar et al. (Mhaskar et al. 2010). 
 
Metastatic bone disease. Bone is the most common site for tumor metastasis in cancer. 
Breast and prostate cancers are most likely to produce bone metastasis but also other 
conditions e.g. kidney and lung cancers commonly give rise to these metastatic tumors. 
Tumor cells can disrupt the metabolism in bone and typically lead to osteoclast stimulation 
which weakens the bone structure and evokes skeletal related events. (Costa & Major 2009) 
The potential benefits of BPs in the treatment of metastatic bone disease were first realized 
in the 1980’s (Coleman 2001). Ever since clodronate, pamidronate, ibandronate and 
zoledronic acid have been intensively studied and have proven efficacy in decreasing 
skeletal related events and pain (Costa & Major 2009). Nowadays, zoledronic acid is the 
standard treatment for these conditions and can be used not only for breast and prostate 
but also for lung, thyroid, kidney as well as head and neck area cancer related bone 
metastases (Rosen et al. 2003). 
 
Hypercalcemia of malignancy. Hypercalcemia of malignancy is a severe condition 
affecting up to 30% of cancer patients during their disease. It is caused by increased bone 
resorption by osteoclasts resulting in an excess release of calcium to blood. Hypercalcemia 
of malignancy leads to psychic disturbances as well as renal failure thus the detection of it 
in a cancer patient is indicative of a short life expectancy. BPs are the most extensively 
studied and the most effective drugs in the treatment of this condition. Intravenous 
pamidronate and zoledronate are the drugs approved in the USA and most widely used, 
but in Europe also treatment with ibandronate and clodronate is common. (Stewart 2005) 
Ibandronate was compared with pamidronate in a randomized trial of 72 patients and was 
found to be as effective as pamidronate in the treatment of hypercalcemia. Moreover, it had 
a longer duration of response and significantly shorter infusion time. (Pecherstorfer et al. 
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2003) In addition, in a clinical trial with 287 patients zoledronic acid was noted to represent 
a more effective and convenient treatment than pamidronate (Major et al. 2001). 
 
Orthopedics. BPs have also been extensively evaluated for orthopedic applications but 
large scale clinical trials are still lacking. For instance, there have been trials investigating 
the efficacy of BPs in bone repair, a complex process where the anabolism and catabolism of 
the bone is responding to an injury. Anabolic phase starts as an inflammatory response to 
injury followed by cellular recruitment and proliferation. The catabolic phase, on the other 
hand, involves the removal of the unwanted tissue and the subsequent bone remodeling. 
Sometimes the catabolism is too intense or mistimed, and BPs can be considered for the 
manipulation of the process. (Morris & Einhorn 2005, Wilkinson & Little 2011) For example, 
alendronate was studied for fracture healing in dogs by Peter et al. and the resorptive phase 
of callus remodeling was found to proceed at slower rate (Peter et al. 1996). Moreover, Omi 
et al. investigated the effect of alendronate on distraction osteogenesis, which is an 
orthopedic technique used e.g. for reconstruction in congenital disorders having the 
drawback of a prolonged healing time. In a rabbit model it was shown that alendronate 
treatment increased the mean BMD without evoking any adverse effects on bone growth. 
(Omi et al. 2007) In addition to bone repair, the use of BPs has been investigated in other 
conditions e.g. in joint arthroplasty, and in bone disorders, such as osteogenesis imperfecta 
and fibrous dysplasia (Morris & Einhorn 2005, Wilkinson & Little 2011). Furthermore, 
etidronate is used in the treatment of heterotopic ossification which is a severe condition 
associated with central nervous system disorders, such as spinal cord injuries, and it 
involves the formation of mature lamellar bone in soft tissues where bone does not 
normally exist (Teasell et al. 2010). 
1.2.2 Antitumor effects of bisphosphonates 
In addition to BPs ability to prevent skeletal related events caused by bone metastases, 
these drugs have also proven to have direct and indirect anticancer activity. In preclinical 
tests, several BPs were found to induce apoptosis in different cell lines, including myeloma, 
breast, prostate and lung cancers. In addition, they can inhibit proliferation, invasion, 
tumor cell adhesion to the extracellular bone matrix and migration, which all can be 
considered as direct effects. Indirect antitumor effects include a reversal of the stimulatory 
effects of some growth factors on cancer cell proliferation, and inhibition of angiogenesis, 
which is a crucial component in tumor growth and progression. Several clinical trials have 
shown increased bone-metastasis-free, disease-free and overall survival in patients 
receiving adjuvant BP therapy, especially in breast cancer patients. (Gnant & Clézardin 
2012, Morgan & Lipton 2010) Zoledronic acid, for example, improved disease-free survival 
as adjuvant therapy in premenopausal breast cancer patients in a clinical trial of 3 years and 
1803 patients (Gnant et al. 2011). In addition, recent studies have indicated that BPs may 
also prevent breast cancer in postmenopausal women treated with BPs for osteoporosis 
(Gnant & Clézardin 2012). In a database study, breast cancer patients were compared to the 
control group and the use of BPs was associated with about a 30% reduction in the breast 
cancer risk (Newcomb, Trentham-Dietz & Hampton 2010).  
1.2.3 Anti-inflammatory effects of bisphosphonates 
Chronic inflammatory process and related immune system activation can induce bone 
modifications, as is the case in chronic joint inflammatory diseases, such as ankylosing 
spondylitis, which affects mainly the spine as well as in rheumatoid arthritis. Thus, the 
properties of BPs could well be utilized in the treatment of these conditions, since it seems 
that BPs are able to improve not only the skeletal disorders but also the general symptoms. 
In fact, BPs have been reported to exert some effects on the immune system: they affect the 
production of pro- and anti-inflammatory cytokines (e.g. interleukin (IL)-1, IL-6, and tumor 
necrosis factor (TNF)-α) and can change the molecular expression associated with the 
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immune processes and anti-inflammatory response. However, there is considerable 
variation in the biological effects of BPs, and contradictory information depending on the 
experimental model, the cell types, administration routes, as well as different BP-structures 
and their concentrations. The clinical studies concerning the anti-inflammatory use of BPs 
are still partially conflicting and they have mostly concentrated on the treatment of 
rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. (Corrado, Santoro & 
Cantatore 2007, Iannitti et al. 2012, Maksymowych 2002) Nevertheless, there have been 
promising results in several publications reviewed e.g. by Santini et al., Corrado et al., and 
most recently by Ianitti et al. (Corrado, Santoro & Cantatore 2007, Iannitti et al. 2012, Santini 
et al. 2004). For example, in a study where rheumatoid arthritis patients received etidronate 
for 18 months, the concentrations of IL-6 as well as urinary deoxypyridinoline (DPD), a 
bone resorption marker, were decreased and there was a significant correlation between 
their levels. These results suggested that IL-6 and DPD had been inhibited by etidronate, 
resulting in an inhibition of the inflammatory activity of rheumatoid arthritis. In addition, 
the BMD was significantly reduced in the control group as compared to the ones receiving 
etidronate treatment. (Hasegawa et al. 2003) In another clinical trial, patients suffering from 
knee osteoarthritis were treated intra-articularly with clodronate for 4 weeks resulting in 
both symptomatic and functional improvements (Rossini et al. 2009). On the other hand, in 
a large two-year study with knee osteoarthritis patients, no improvement in the signs and 
symptoms of the disease by patients receiving risedronate as compared to placebo was 
observed. However, a reduction in the level of a marker of cartilage degradation was noted. 
(Bingham et al. 2006)  
Osteoporosis is a well recognized feature of ankylosing spondylitis. Osteoclast-mediated 
bone resorption is stimulated by the release of certain cytokines including TNF-α and IL-6. 
In ankylosing spondylitis, the increased concentrations of these cytokines constitute a part 
of the underlying inflammatory disease activity. As a result, bone resorption is increased, 
and this induces osteoporosis. The study of Kang et al. suggested that an anti-TNF-α agent 
might work together with BP to increase the BMD of ankylosing spondylitis patients. In 
addition, a significant relationship was detected between the reduction of inflammation 
and the gain of BMD. (Kang et al. 2011) 
1.2.4 Bisphosphonates as radiopharmaceuticals  
Bone scintigraphy, a technique involving bone scanning with radiochemicals, is a useful 
way to identify bone pathology e.g. in the metastatic bone disease, as well as how far the 
disease has spread and thus it can monitor response to therapy (Ben-Haim & Israel 2009). 
Technetium-99m (99mTc) is the most widely used radionuclide for single photon emission 
computed tomography (SPECT) imaging because of its almost ideal nuclear properties (half 
life = 6.02 h; γ-energy = 140 keV), low-cost and widespread availability. BPs have been used 
as radiopharmaceuticals for SPECT imaging for over 30 years. BPs chelate technetium 
efficiently, while still maintaining their affinity for HA and thus have the ability to target 
bone. (Palma et al. 2011) The uptake of 99mTc-labelled BPs in the bone reflects increased 
vascularity and osteoblastic activity, thus allowing the detection of the areas of active 
remodeling (Ben-Haim & Israel 2009). 99mTc-labelled etidronate was first reported as a new 
bone imaging agent at the beginning of the 1970’s (Castronovo & Callahan 1972, 
Subramanian et al. 1972). Subsequently, 99mTc-medronate was found to be superior to 99mTc-
etidronate due to its faster blood clearance and lower distribution in the soft tissues 
(Subramanian et al. 1975). In addition, 99mTc-oxidronate (which differs from medronate in 
that it has a hydroxyl group in the central carbon) was introduced as a bone scanning agent 
with improved HA binding properties (Bevan et al. 1980).  
Nowadays, 99mTc-medronate and 99mTc-oxidronate are the only 99mTc-based 
radiopharmaceuticals approved for bone imaging (Palma et al. 2011). The use of 99mTc-
labelled BPs in bone scintigraphy is the most commonly used method because of its ready 
availability, high sensitivity and low cost. However, 99mTc-labelled BPs possess relatively 
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low specificity. (Ben-Haim & Israel 2009) In addition, before obtaining bone images, 2 to 6 
hours waiting time after the injection of the radiopharmaceutical is needed. A reduction in 
this time interval in order to lessen the burden of patients would be possible if there was a 
radiopharmaceutical with higher affinity for bone. The phosphonate groups of 99mTc-
medronate and -oxidronate offer the binding site for both radioactive technetium and the 
calcium of HA, and this might decrease their accumulation in bone. Thus, new bifunctional 
structures have been synthesized and investigated. In these types of molecules, the BP-
moiety acts as a carrier to the bone and the radiometal chelating group is separated in the 
molecule, allowing these groups to function independently and effectively. Several novel 
structures have been developed with higher rates of binding as well as higher affinity for 
HA as compared to 99mTc-medronate or -oxidronate. (Ogawa & Saji 2011) 
1.2.5 Bisphosphonates and parasitic diseases 
Parasitic protozoan diseases constitute the most widespread human health problem in the 
world. Malaria, which is caused by Plasmodium spp., alone is responsible for approximately 
one million deaths every year. Conventional therapy is expensive and unfortunately 
resistance to antimalarials is widespread. Therefore, the development of new, inexpensive 
drugs for the treatment is of vast importance. (No et al. 2012) BPs have been shown to exert 
activity against several different protozoan parasites. Martin et al. explored the in vitro 
activity of 19 BPs against Trypanosoma cruzi, Trypanosoma brucei, Leishmania donovani, 
Toxoplasma gondii and Plasmodium falciparum. These parasitic protozoa cause Chaga’s 
disease, African sleeping sickness, leishmaniasis, toxoplasmosis and malaria, respectively. 
Nanomolar to low-micromolar IC50 values were found against all of these parasites. 
Risedronate was one of the most effective compounds to reduce the parasite proliferation 
rate of T. brucei, T. cruzi and L. donovani and FPPS was suggested as the possible target. On 
the other hand, NNBPs had higher activity against T. gondii and P. falciparum. (Martin et al. 
2001) Moreover, risedronate was shown in a mouse model to inhibit the growth of 
Cryptosporidium parvum, a major cause of diarrheal disease worldwide (Moreno et al. 2001).  
The FPPS of T. cruzi and T. brucei was shown also to be the target of 1-hydroxy-1,1-
bisphosphonates derived from fatty acids (Figure 5). Some of these compounds were even 
more effective inhibitors than the representative NBPs, and the presence of the hydroxyl 
group in the central carbon was shown to be crucial for the biological activity. (Szajnman et 
al. 2003) Later, Ghosh et al. published results concerning the activities of over 100 BPs 
against both Entamoeba histolytica and P. falciparum. E. histolytica causes amebic dysentery, a 
disease which is the third leading global cause of human morbidity and mortality caused 
by parasitic protozoa. From the four most active compounds including aminomethylene-
1,1-bisphosphonates containing biphenyl, phenoxyalkyl and arylalkyl side chains (Figure 5), 
only one, a 1-hydroxy-3-(2-phenoxyethyl)aminopropylidene bisphosphonic acid (Figure 5) 
was able to inhibit FPPS while for the others no correlation was observed between the FPPS 
inhibition and E. histolytica growth. Hence, it was concluded that there must be additional 
targets other than FPPS to explain whydrugs are able to inhibit E. histolytica. In general, 
simple alkyl-BPs and NBPs with hydrophobic side chains had much greater inhibitory 
activity against E. histolytica and P. falciparum in comparison to the NBPs used in the bone 
resorption therapy, such as risedronate, alendronate and pamidronate. Due to the presence 
of hydrophobic side chains in the active compounds, the membrane transport was 
speculated to play an important role in the growth inhibition. (Ghosh et al. 2004)  
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Figure 5. Examples of bisphosphonates active against protozoan parasites (Ghosh et al. 2004, 
No et al. 2012, Recher et al. 2013, Szajnman et al. 2008, Szajnman et al. 2003)  
 
Subsequently, a new group of BPs, 2-alkylaminoethyl-1,1-bisphosphonates (Figure 5), 
were synthesized for the inhibition of T. cruzi FPPS (Szajnman et al. 2008). However, these 
compounds appeared to have a dual action of T. cruzi growth inhibition, since they also 
inhibited T. cruzi squalene synthase (Rodrígues-Poveda et al. 2012). Another target was 
found since analogues of zoledronate and risedronate were shown to exert activity against 
P. falciparum both in vitro and in vivo. These lipophilic analogues, in which the OH-group of 
zoledronate or risedronate was removed to prevent bone binding and the ring alkylated to 
enhance lipophilicity (Figure 5), were able to inhibit the Plasmodium GGPP synthase which 
was thus proposed as a promising novel target for antimalarial drugs. (No et al. 2012) 
Recently, novel sulfur-containing BPs were shown to have antiparasitic activity. In 
particular, compounds with long alkyl chains (Figure 5) exhibited potent activity against T. 
gondii and T. cruzi FPPS. (Recher et al. 2013) 
The results presented above clearly point to BPs being potential candidates for the 
chemotherapy of various infectious diseases caused by parasitic protozoa. However, the 
design of new optimized BP-compounds with improved activities is still on-going but no 
clinical trials have yet been performed. 
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1.2.6 Bisphosphonates in dentistry 
Periodontitis is one of the most common diseases in dental clinics. It involves a progressive 
resorption of alveolar bone around the teeth and inflammation caused by plaque bacteria. 
With the anti-inflammatory and anti-bone-resorbing effects of BPs in mind, a BP analogue 
with sulfur and benzene ring in the central carbon substituent (disodium dihydrogen-4-
[(methylthio)phenylthio]methanebisphosphonate) was investigated for the treatment of 
periodontitis in rats and achieved promising results: the alveolar bone loss was 
significantly prevented and the formation of dental calculus inhibited. (Shinoda et al. 2008) 
In clinical studies, BPs have been evaluated as adjunct agents for human periodontal 
treatment resulting in significant clinical improvement compared to placebo (Kirkwood et 
al. 2007, Lane et al. 2005). 
The need to deliver BPs locally at the site of interest, e.g. during the dental surgical 
processes has lead to the development of delivery systems applicable for use in dentistry, 
such as BP loaded into microspheres and in gel formulations. An alendronate-gel was 
tested in the clinic for the treatment of bone resorptive lesions of periodontitis with good 
results: the bone formation was increased with straightforward administration of the gel 
and without the side effects associated with systemic therapy. (Nafea et al. 2007, Reddy & 
Kumar 2005) The local delivery of the alendronate-gel has also been tested in the clinic in 
conjuction with scaling and root planing for the patients with chronic and aggressive 
periodontitis as well as those with chronic periodontitis related to type two diabetes. All the 
trials achieved good results as compared to the placebo and this was thought to reveal a 
new direction in the treatment of periodontitis. However, the treatment duration of the 
trials was only six months, and thus further long-term clinical trials will be required to 
determine the true clinical, histological and radiographic benefits of alendronate on bone 
healing. (Pradeep et al. 2012, Sharma & Pradeep 2012, Sharma 2012) Another BP-gel has 
been investigated for the prevention of the formation of a smear layer during root canal 
preparation. The etidronate-gel had superior calcium chelating capacity and ability to 
prevent the smear layer formation as compared to the currently marketed paste-type 
chelator products containing ethylenediamine tetraacetate (EDTA) and hydrogen peroxide. 
(Girard et al. 2005)  
1.3 NON-MEDICAL APPLICATIONS OF BISPHOSPHONATES 
1.3.1 Bisphosphonate metal complexes and their crystal structures 
Geminal BPs are well known as effective metal chelators and the chelation properties of a 
great variety of BP-structures with different metal ions have been intensively studied. In 
order to investigate the metal chelation properties of BPs, many BP metal complexes have 
been structurally characterized by either a single crystal diffraction technique or from X-ray 
powder diffraction data. These experiments have revealed a huge amount of variable 
structural units and motifs with the structures ranging from one-dimensional (1D) chains 
through two-dimensional (2D) layers to three-dimensional (3D) coordination frameworks. 
The factors affecting the formation of complexes include the properties of the substituents 
in the central carbon (e.g. length and rigidity), the extent of protonation of the phosphonate 
groups, the geometrical preferences and the charge of the coordinated metal ion as well as 
the presence of other ions or molecules in the starting mixture. Because of the suitable steric 
arrangement of phosphonate groups, BPs are capable of chelating metal ions and forming 
stable complexes, even in relatively acidic solutions. (Matczak-Jon & Videnova-Adrabińska 
2005) 
Generally, the bidentate or bisbidentate chelation by BPs is very common, however, the 
formation of bis-complexes through the coordination of a second ligand is considered to be 
less favored because of the high electrostatic repulsions between the negatively charged 
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phosphonate groups around the metal ion. The bidentate chelation by using one oxygen 
atom of each phosphonate group resulting in the formation of a six-membered ring is a 
widely accepted coordination mode found in many BP metal complexes. (Matczak-Jon & 
Videnova-Adrabińska 2005) The hydroxyl group of the central carbon can also participate 
in the metal chelation through bidentate or tridentate binding but it almost invariably 
remains in the protonated form (Galezowska & Gumienna-Kontecka 2012).  
AminoBPs with a primary or secondary nitrogen atom, always exist as zwitterions in the 
solid state, and the protonated nitrogen involved in both inter- and intramolecular 
hydrogen bonding affects strongly the molecular organization, thus reflecting the ability of 
complex formation by the compound (Matczak-Jon & Videnova-Adrabińska 2005). Figure 6 
shows an example of a crystal structure of the complex formation between an aminoBP ((5-
amino-1-hydroxypentylidene)bisphosphonic acid) and Cd2+. On the right side of the figure, 
where the binding of one molecule with Cd2+ is presented, the formation of the six-
membered ring, the protonation of the amino group at the end of the alkyl chain as well as 
the unprotonated hydroxyl group in the central carbon can be clearly distinguished. In the 
left side part of the figure, in which several aminoBP molecules are chelating Cd2+ ions, the 
packing mode of a linear polymeric chain, where the metal ions are bound to five oxygen 
atoms belonging to four different phosphonate groups and to the hydroxyl group in the 
central carbon, is shown. 
 
 
Figure 6. Crystal structure of the (5-amino-1-hydroxypentylidene)bisphosphonic acid Cd2+ 
complex. On the right side, the structure of a single molecule complexed with Cd2+ and on the 
left side the image of the packing mode. 
 
The amount of studies about the metal chelation of different BP-structures is extensive; 
according to Chemicals Abstracts there are about 500 references devoted to the BP crystal 
structures containing metal ions. Consequently, only selected examples about BP metal 
complexes are presented here. The complexation of Cu2+, Fe3+ and Al3+ has been studied, for 
example, by potentiometric titrations and NMR spectroscopy with 1-phenyl-1-
hydroxymethylenebisphosphonic acid and its analogues proving the effective binding of 
the cations (Gumienna-Kontecka et al. 2002a, Gumienna-Kontecka et al. 2002b). The 
complexation of lanthanides and actinides by BPs has been investigated e.g. with medronic 
acid, etidronic acid and vinylidene bisphosphonic acid by determining stability constants, 
and using TGA as well as FTIR (Nash 1997). Matveev et al. studied the chelation of several 
divalent metal cations by alkylaminoBPs and their analogues with dimethyl substituted 
amino groups. No effect was noted when changing the chain length (n = 1-3) on either the 
23 
 
 
efficiency or the selectivity of complexation, but methylation of the amino group did 
decrease the stability of the complexes. (Matveev et al. 1998) Kunnas-Hiltunen et al. 
introduced four novel BP metal complexes and their crystal structures measured by X-ray 
single-crystal diffraction. In clodronate cobalt(II) complex, the 3D hydrogen bonding 
interactions occurred when the phosphonate oxygen atoms served as hydrogen bonding 
acceptors and the 3D hydrogen bonding network was also seen in copper risedronate. 
Instead, the addition of diester functions to clodronate in the cobalt(II) and manganese(II) 
complexes of clodronate dibenzoyl derivatives resulted in 2D dense packing modes 
without any voids accessible to solvent. (Kunnas-Hiltunen et al. 2010) 
1.3.3 Utilization of the metal chelating properties of bisphosphonates 
Despite the interest in the metal chelation properties of BPs, the utilization of this 
characteristic has been somewhat restricted, apart from the Ca2+ or Mg2+ -chelation related to 
their actions in the body. One possible medical application could be the removal of harmful 
or too high concentrations of metal ions from the body. For example, catechol-BP 
conjugates have been designed and proposed for use in the treatment of metal poisonings 
(Xu et al. 2004). In addition, a dipodal BP ligand has been found to confer significant 
benefits after UO22+ contamination in rats in vivo. The administration of the BP increased 
U(VI) excretion and reduced uranyl deposition in the kidney by around 50%. (Sawicki et al. 
2008) Sometimes BP metal complexes can be more effective in their function than the 
corresponding free ligands. By combining the biological properties of the metal ion and 
ligand, one can obtain metal complexes which may possess multiple mechanisms of action. 
Moreover, the delivery, bioavailability and biodistribution of the ligand may be improved 
due to the complex formation, since the changes affect the solubility, lipophilicity and the 
formation of highly charged species. Alendronate and pamidronate complexes with Cu(II), 
Co(II), Mn(II) and Ni(II) were studied and tested against the parasite Trypanosoma cruzi. The 
complexes were demonstrated to be potent inhibitors of T. cruzi in vitro and the activity of 
the ligand was shown to improve by the metal chelation. (Demoro et al. 2012)  
BPs are effective solvent extraction reagents for actinides, such as U(VI), Am(III), and 
Th(IV) (Chiarizia, McAlister & Herlinger 2001, Herlinger et al. 1997). Herlinger et al. 
deduced that the metal extraction by P,P’-di(2-ethylhexyl)methylenebisphosphonic acid 
(Figure 7), in which two of the acidic protons of BP moieties were replaced by alkyl groups, 
was dependent on reaction conditions: at very low metal ion concentrations, the extraction 
seemed to proceed through solvation process, whereas at high concentrations, the 
extraction occured through ion exchange where the acidic protons of BP were displaced by 
the metal ion (Herlinger et al. 1997). In addition, non-geminal BPs with the same ester 
substituents but different amounts of carbons in between the two BP groups (ethylene, 
butylene, benzene; see Figure 7) were studied for their metal extraction properties. The 
extraction efficiency for the metal ions was found to decrease as the alkyl chain length 
between the phosphonate groups increased but not as much as would be expected based on 
the increased entropy of the large chelate size. However, the BP containing the benzene 
ring behaved more similarly with the methylene than the ethylene analog due to the 
rigidity of the benzene ring. (Chiarizia, McAlister & Herlinger 2001, Otu et al. 2002) 
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Figure 7. Structures of bisphosphonates used in the metal extraction studies and the 
commercially available bisphosphonate resins (Chiarizia et al. 1997, Chiarizia, McAlister & 
Herlinger 2001, Herlinger et al. 1997, Horwitz, Chiarizia & Dietz 1997, Otu et al. 2002) 
 
Furthermore, metal ions have been separated from aqueous solutions by BP-based ion 
exchange and extraction chromatographic resins. In an extraction chromatographic resin, 
Dipex®, the liquid BP (previously mentioned P,P’-di(2-ethylhexyl)methylenebisphosphonic 
acid) is supported on an inert polymeric substrate, whereas in an ion exchange resin, 
Diphonix®, the geminally substituted BP groups (Figure 7) are chemically bonded to a 
styrene-based polymer matrix. These materials are commercially available and have several 
applications e.g. for the separation and pre-concentration of radionuclides from aqueous 
solutions or for the removal of metal ions from waste water. (Chiarizia et al. 1997, Horwitz, 
Chiarizia & Dietz 1997) In addition to resins, BPs can also be attached to other materials e.g. 
to agricultural residuals for utilization as low-cost biomass-based adsorbents. Etidronate 
was recently bound to buckwheat hulls and the resulting adsorbent was successfully tested 
with waste gold solution and it was found to be able to adsorb Au3+ ions. (Yin et al. 2013)  
BPs have also been studied in the area of material chemistry extensively especially in the 
1990’s as hybrid inorganic-organic and microporous materials. The wide possibilities to 
modify BP structures and their effective chelation with several metal ions mean that BPs are 
a particularly versatile target of research in this field. In addition, the use of BPs in 
multilayer film assemblies has attracted attention because of the straightforward 
preparation and physical stability of these thin films. The growth of thin films involves the 
adsorption of BPs and metal ions sequentially on a derivatized substrate which leads to 
layer-by-layer growth. These multilayer thin films based, for example, on Si and glass 
substrates could be basic elements of new devices utilized in semiconductor technology. 
Thus, potential applications of these materials can be found in electro-optic, photorefractive 
and second harmonic generation devices. (Neff et al. 2000, Snover et al. 1996) Microporous 
materials, on the other hand, are of great importance as molecular sieves, catalysts, ion-
exchangers and sensor materials due to their ability to interact with atoms, ions and 
molecules throughout almost the entire mass of the material instead only at their surfaces. 
Lohse and Sevov were the first to demonstrate that microporous BP with an inorganic 
backbone and hydrophobic channels (Co2(O3P-CH2-PO3)) was accessible. (Gómez-Alcántara 
et al. 2006, Lohse & Sevov 1997) Recently, Wharmby et al. used isoreticular synthesis for the 
preparation of crystalline microporous Co(II) and Ni(II) BPs with larger pore sizes which 
have possible uses in gas adsorption and separation, as catalysts or catalyst supports, as 
well as in drug delivery (Wharmby et al. 2011). 
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1.3.3 Bisphosphonates and plants 
In addition to the extensive research of BPs on their actions in humans, their influence on 
plant metabolism has been under investigation. The herbicidal effects of BPs were first 
discovered in 1979 according to the patent literature but this did not attract much attention 
until 1995. Since then several BPs have been designed and tested for their herbicidal 
properties, and attempts have been conducted to elucidate the molecular targets of these 
compounds in plants. (Kafarski, Lejczak & Forlani 2000) The fourth generation BPs, N-
substituted aminomethylenebisphosphonic acids are a group of BPs exhibiting herbicidal 
activity that have attracted considerable interest. Despite the attempts to elucidate their 
mechanism of action, this has remained partly unclear. Initially, N-pyridyl-substituted 
aminomethylenebisphosphonic acids were suggested to act as possible inhibitors of 3-
deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase which is the first enzyme in 
the biosynthetic enzymatic chain to the aromatic amino acids, the shikimate pathway. 
DAHP synthase occurs in plants as two distinct isoenzymes: one form is located in the 
cytosol and requires the presence of divalent cations (Co2+ or Mg2+) and the other, plastidial 
form, does not demand cations for its activity but is clearly stimulated by Mn2+. The 
inhibition of Co2+-dependent isoenzyme was shown to occur due to the metal chelation 
properties of the tested compounds but some of the compounds displayed activity for the 
inhibition of the Mn2+-dependent form, which was not solely attributable to metal chelation. 
(Forlani, Lejczak & Kafarski 1996) 
 
 
Figure 8. Some herbicidally active BPs (Cromartie, Fisher & Grossman 1999, Forlani et al. 2007, 
Forlani et al. 2013, Forlani, Lejczak & Kafarski 2000, Oberhauser et al. 1998) 
 
Contrary to these results, Oberhauser et al. noted that N-2-(3-
methylpyridyl)aminomethylenebisphosphonic acid (Figure 8) inhibited GGPP-synthase 
(Oberhauser et al. 1998). On the other hand, Cromartie et al. suggested that the herbicidal 
effect of this compound was attributable to the inhibition of FPP synthase. They also 
proved that there was a correlation between the half maximal inhibitory concentration 
(IC50) values measured in a daffodil chromoplast assay and the herbicidal activity of 
aminoBPs: with IC50 values less than 40 nm compounds showed good herbicidal activity 
whereas with values higher than 200 nm, there was little or no activity detected. 
(Cromartie, Fisher & Grossman 1999) Furthermore, BPs were used to elucidate the role of 
the plant vacuolar pyrophosphatase present in the vacuolar membrane by testing the 
inhibitory effects of different BP structures. It was hoped that these experiments would 
reveal some information about the active site of the enzyme. Small aliphatic aminoBPs were 
found to be effective and competitive inhibitors. The most favorable BP structures for the 
inhibition contained amino and hydroxyl groups, possibly due to the interaction of the 
groups with carboxy or other charged residues near to the catalytic site. Thus, based on the 
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observations, it was postulated that the catalytic site might be located in a hydrophilic 
pocket within the enzyme. (Gordon-Weeks et al. 1999) 
Later, new evidence supported the multiple mode of action of N-substituted 
aminomethylenebisphosphonic acids, since the herbicidal properties of N-2-(5-chloro-
pyridyl)aminomethylenebisphosphonic acid (Figure 8) were suggested to be due to the 
inhibition of both amino acid and glutamine biosynthesis (Forlani, Lejczak & Kafarski 
2000). Moreover, 3,5-dichlorophenylaminomethylenebisphosphonic acid (Figure 8) was 
noted to be an effective inhibitor for P5C reductase, an enzyme catalyzing the last step of 
proline biosynthesis. This aromatic chlorinated compound, however, is most probably 
readily degradable and thus does not hold potential as a useful herbicide. (Forlani et al. 
2007) Based on this lead molecule, new compounds not containing halogen substituents 
were recently found to be active inhibitors of P5C reductase acting in the micromolar range. 
Nevertheless, the most active compounds were again halogenated (Figure 8, last two 
compounds) and in the other compound there was a carbon atom between the central 
carbon and the nitrogen atom. (Forlani et al. 2013) 
Meanwhile, several analogues of N-substituted aminomethylenebisphosphonic acids 
have been synthesized to examine the structural requirements of the compounds for the 
herbicidal activity as well as for the target receptors, but it seemed to be difficult to identify 
clear structure-activity relationships (Chuiko et al. 1999, Kafarski et al. 1997). Based on the 
studies of the herbicidal effects of BPs, these compounds can be considered as a 
heterogeneous group with various modes of action. 
Although there is now active ongoing research on BPs with herbicidal activities, many 
other possible actions of BPs in plants have not been investigated. The metal chelation 
properties of BPs have been acknowledged to be important in plant metabolism but the 
possible utilization of these properties in other applications, such as phytoremediation, has 
not been reported. However, the use of plants to elucidate the actions of BPs was 
postulated by Manzano et al. The effects of etidronate, clodronate, alendronate and 
pamidronate were tested with Arabidopsis thaliana in culture medium by examining the rate 
of seed germination, the growth of the primary and secondary roots and the colour of the 
leaves as an indicator of the presence of chlorophyll. Generally, the inhibitory effects were 
strongest with alendronate, followed by clodronate, pamidronate, and finally etidronate. 
Clodronate, pamidronate and alendronate affected both the growth of the primary root and 
the number and the length of the secondary roots. In addition, alendronate evoked the total 
loss of chlorophyll. These effects were suggested to result from the actions of BPs on the 
mevalonate pathway of Arabidopsis thaliana. (Manzano et al. 2012) 
1.3.4 Bisphosphonates in gels 
Gels containing BPs have been investigated for both medical and non-medical purposes. 
For example, the mechanism of the formation of organogels of BP metal complexes has 
been investigated. The Fe3+ complexes of non-geminal bisphosphonates having two ester 
functions and a long alkyl chain (n = 6, 10) between the phosphonate groups formed 
thermally relatively stable gels in DMSO after five weeks and three hours, respectively. 
According to the results of rheological measurements, X-ray diffraction studies and small 
angle neutron scattering measurements, the formation of the complexes seemed very rapid 
and was followed by their aggregation into inverted giant rodlike micelles with narrow 
cross-sections. Thus, it has been speculated that these complexes might have applications in 
hydraulic fracturing. However, Al3+, B3+ or Zr4+ -complexes of the bisphosphonate (n = 10) 
were not able to form gels; generally, a phosphonic acid monoester displayed better gel 
formation properties as compared to the bisphosphonates. (George et al. 2006, George, 
Funkhouser & Weiss 2008)  
There are publications of odontological applications using gels containing BPs, which 
have been discussed in detail in the chapter Bisphosphonates in dentistry (1.2.6). Etidronate 
gels, for instance, have been studied for root canal repair as well as for the treatment of 
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periodontitis (Girard et al. 2005, Reddy & Kumar 2005, Sharma 2012). A BP-containing gel 
has been found to function as a good scaffold on which to grow cells, since pamidronate 
incorporated into a sodium silicate gel coating cellulose-based scaffold has been found to 
affect both the proliferation and vitality of human fetal osteoblasts (Ponader et al. 2008). 
Research has been conducted into the possibility of using silica xerogels as carriers for BP-
platinum complexes to function as antitumorial agents. Pt-BP complexes are of interest in 
the treatment of bone tumors, since in animal trials they displayed superior therapeutic 
activity over cisplatin, a well known anti-cancer drug. According to Iafisco & Margiotta, the 
calcium-containing sol-gel derived silica xerogels are ideal biocompatible matrices for Pt-BP 
complexes for the local administration at the site of bone tumor. The reason for this is that 
by varying chemical-physical features of the xerogel, such as porosity and surface area, the 
adsorption and release of the complexes can be modified to be suitable for specific 
therapeutic applications. (Iafisco & Margiotta 2012, Margiotta et al. 2007) 
Some BP containing hydrogels have been reported to be related to applications of the 
treatment of bone resorption, wound healing and removal of radionuclides from wounds 
(Rayment et al. 2008, Xu et al. 2008, Yang et al. 2012). An injectable Ca2+•BP-hyaluronic acid 
hydrogel has been developed to support biomineralization, which is essential for the 
growth of the surrounding bone. This hybrid hydrogel material was shown to be formed 
via a direct transition from the non-ordered solution phase within a very short time and 
under physiological conditions; it was able to further become mineralized in vitro in a Ca2+-
containing phosphate buffer. (Yang et al. 2012) Furthermore, alendronate tethered to a 
poly(2-hydroxy methacrylate) hydrogel has been shown to inhibit matrix 
metalloproteinases, which have increased activity in chronic wound fluid, and thus to 
evidence for an improvement in ulcer healing (Rayment et al. 2008). In addition, BP-
containing supramolecular hydrogels have been developed for the possible treatment of 
uranium-contaminated wounds taking advantage of the chelation properties of BPs (Xu et 
al. 2008). 
1.3.5 Other bisphosphonate applications  
In addition to the applications mentioned previously, BPs have been investigated for use in 
many other fields some of which deserve to be mentioned here. For example, BPs have been  
shown to exert an inhibitory effect on the atherosclerotic process, i.e. the accumulation of 
lipids and fibrous elements in the arteries. More precisely, in small clinical trials BPs have 
been shown to inhibit arterial calcification and lower the carotid artery intima-media 
thickening (i.e. the thickening of the two innermost layers of the arterial wall). However, 
larger clinical studies will be needed to verify these preliminary results. (Santos, Cavalcanti 
& Bandeira 2012, Ylitalo 2002) Furthermore, BPs exhibited potent antioxidant activity in 
vitro in some assays where their reducing potential and inhibition of lipid peroxidation 
were evaluated (Balakrishna et al. 2011, Dombrecht et al. 2004). As a result of the 
continuous research into BP structures and their derivatives as well as the variable 
functions of BPs, the numbers of applications in different fields, including those presented 
in this thesis, are expected to increase substantially in the near future. 
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2 Aims of the study 
Despite intensive research conducted into a significant group of BPs with respect to their 
medical use, i.e. the alkylaminoBPs, there was no consistent data about their 
physicochemical properties. Thus, it was deduced to examine a series of alkylaminoBPs in a 
systematic manner (Paper I). Previously, it had been discovered in our research group that 
one of the alkylaminoBPs with a long alkyl chain length displayed extremely low solubility 
in water and a great ability to chelate metal ions in aqueous solutions. The discovery of this 
new sparingly soluble BP material triggered the need to study the usage of its properties in 
relevant fields, e.g. in waste water and soil purification (Papers II and III). Another goal 
was to prepare and investigate new BP structures in order to identify other usable 
compounds for metal ion removal from aqueous solutions (Paper II). During the solubility 
studies of the synthesized BPs, one of the compounds surprisingly displayed gelation 
properties in water. This observation was the stimulus for conducting a detailed study of 
the chemical and physical nature of novel BP organo- and hydrogels (Paper IV). 
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3 General methods 
The generally used methods are described briefly in this chapter; more detailed information 
can be found in the original papers mentioned in parenthesis.  
3.1 SYNTHESIS OF THE BISPHOSPHORUS COMPOUNDS USED IN THE 
EXPERIMENTS 
A total of thirty BPs were synthesized for use in these experiments (Table 3), some of them 
being new (1e-g, 1i, 1j, 3a-c, 4a, 5d-5g) and the others well-known compounds. The 
syntheses of the BPs used in the experiments in Papers I-IV were accomplished according 
to the previously published methods (Kieczykowski et al. 1995, Mohamady & Jakeman 
2005, Mong, Niesor & Bentzen 1987, Szajnman et al. 2005, Turhanen & Vepsäläinen 2004, 
Vepsäläinen, Nupponen & Pohjala 1991) mostly from commercially available starting 
materials.  
 
Table 3. The bisphosphonates (BPs) synthesized and used in the experiments in papers I-IV 
 
BP R1 R2 n Yield (%) Salt form/esters Papers General structure 
1a NH2 OH 2 22 disodium I  
 
1b   3 85  I & III 
1c   4 86  I 
1d   5 88  I & III 
1e   7 75  I & III 
1f   8 63  I 
1g   9 66  I & II 
1h   10 100  I-III 
1i   11 85  I & II 
1j   15 78  I 
2a H OH 1 88  III 
2b   4 61 monosodium II  
2c   5 72 monosodium II  
2d   8 77 1,5-sodium II  
2e   10 74  II  
3a Ph OH 2 31 disodium II  
3b   4 39 1,5-sodium II  
3c   7 36  II  
4a H NH2 8 19  II  
4b   9 28  II  
5a H H 0 100  III  
5b   7 40  II  
5c   10 41  II  
5d   11 37  IV  
5e   12 28  II & IV  
5f   13 25  IV  
5g   16 49  II  
6 Cl Cl 0 94 disodium III  
7 OCOCH3 CH3 0 83 disodium/P,P´ 
-dimethylester 
IV  
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3.2 NMR SPECTROSCOPY AND ELEMENTAL ANALYSIS  
The purities of the synthesized compounds were confirmed by solution state NMR 
measurements (Papers I-IV). 1H, 31P and 13C spectra were measured on a Bruker Avance 500 
DRX spectrometer operating at 500.1, 202.5 and 125.8 MHz, respectively. Sodium 3-
(trimethylsilyl)-1-propionic acid (TSP) in D2O or tetramethylsilane (TMS) in MeOD and 
CDCl3 were used as internal standards in the 1H and 13C measurements, and 85% H3PO4 as 
an external standard in the 31P measurements. Solution state NMR was also used for 
variable temperature measurements of the BP-gel samples. 
Solid state 13C and 31P spectra were measured on a Bruker AMX-400 FT NMR 
spectrometer equipped with a magic-angle spinning probehead operating at 100.61 MHz 
and 161.97 MHz and the samples were packed in zirconia rotors. The spinning rates, 
contact times and delays of each experiment are presented in detail in Papers I-II & IV. 
Elemental analyses (C, H, N) were accomplished with a ThermoQuest CE Instruments 
EA 1110-CHNS-O elemental analyzer (CE Instruments, Milan, Italy). Phosphorus contents 
were determined at 880 nm in a Jasco V-530 spectrophotometer using the molybdenum 
blue method as described below (3.4). 
3.3 THERMAL ANALYSIS 
Thermal decomposition paths with evaluation of crystal water content were obtained in 
parallel with two instruments; Perkin Elmer STA 6000 thermogravimetric TG/DTA and 
Perkin Elmer TGA 7 analyzers (Paper I). In Paper III, the first mentioned instrument was 
used for the analysis. Measurements were carried out in an open platinum crucible under 
an atmosphere of air (flow rate of 45 ml/min) with a heating rate of 5 °C/min over the 
temperature range of 25-700 C. The temperature calibration of STA 6000 instrument was 
made using the melting points of indium (156.60 °C) and zinc (419.5 °C) standards. For 
TGA 7, the magnetic Curie-point calibration technique (Alumel, Ni, Perkalloy, Fe) was 
used. The weight balance of both instruments was calibrated by measuring a standard 
weight of 50 mg at room temperature. The sample weights used in the measurements were 
about 4-8 mg, and for each bisphosphonate, it was attempted to keep the same weight on 
both instruments.  
3.4 THE DETERMINATION OF PHOSPHORUS CONCENTRATION 
The modified molybdenum blue method (APHA 2005) was used for the determination of 
phosphorus contents in the BP sample solutions, and the solubility experiments were based 
on this method (Papers I, II & III). For the phosphorus determination, BPs were first 
converted to orthophosphate ions via oxidative cleavage of the phosphorus-carbon (P-C) 
bonds by persulphate treatment in an acidic medium at elevated temperature and then 
allowed to react with molybdate. Ammonium molybdate and antimony potassium tartrate 
react with orthophosphate in an acidic medium, forming a phosphomolybdic acid that is 
reduced by ascorbic acid to the intensely colored molybdenum blue complex which can be 
determined colorimetrically. The detailed description of the method is presented here, since 
it is not included in the original articles.  
Aqueous solutions of BPs were digested in the presence of sulphuric acid and potassium 
persulphate (K2S2O8) to convert or hydrolyze the phosphorus of organic compounds to 
orthophosphate (PO43-). Sample solutions (1.00 ml) were transferred into a series of 5 ml test 
tubes, 1.00 ml 0.040 M H2SO4 and 0.200 ml of 5% K2S2O8 solutions were added. The 
solutions were mixed well, heated in a boiling water bath for 30 min and cooled to room 
temperature. In the case of BPs with low solubilities, microwave digestion was used. An 
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accurately weighed sample (200-500 mg) and 3.0 ml conc. ultrapure acid(s) (HNO3, HCl, 
H2SO4, HNO3/HCl (1:3) or HNO3/HCl/H2SO4, (1:1:1)) were transferred to a Teflon digestion 
vessel and the sample was digested for 20 min at 40%, for 20 min at 50% and for 12 min at 
70% power (internal pressure 100 psig). In the case of H2SO4/K2S2O8 digestion, 500 mg of 
solid K2S2O8 was added into a Teflon vessel prior to the digestion procedure. The solutions 
were diluted to 50 ml with Milli-Q water. 
A volume of 40 μl of 5% ascorbic acid reducing solution was added to the sample 
solution and the mixture was shaken well, after which 40 μl ammonium molybdate colour 
reagent (containing antimony potassium tartrate) was added. The mixture was shaken well 
and the absorbance was measured at 880 nm in a Jasco V-350 UV/Vis spectrophotometer 
within 10-30 min against a reagent blank, prepared simultaneously. Calibration standards 
were prepared by diluting an appropriate amount of phosphorus stock solution in 0.04 M 
H2SO4 and were treated in similar way as the samples. A calibration graph (absorbance as a 
function of mg/l P) was used for the determination of the amount of BPs. 
3.5 SOLUBILITY EXPERIMENTS  
The estimated solubility of synthesized compounds in aqueous solution was determined at 
constant room temperature (21.0 °C) by preparing a saturated solution in Milli-Q water 
without buffering (Papers I & II). The mixture containing an excess of the compound was 
first agitated for 30 min with a magnetic stirrer and before taking the sample, the mixture 
was allowed to stand for 24 h without stirring. The sample (approx. 5 ml) was taken from 
the liquid above the solids, pH was measured and the sample was filtered through 0.2 μm 
membrane filter to remove any possible insoluble particles. The sample solutions were 
taken for the determination of the phosphorus concentration which was measured in a 
spectrophotometer using the modified molybdenum blue method. The measured 
phosphorus concentration was used for calculating the solubility of the compound.  
3.6 METAL ION RECOVERY EXPERIMENTS  
The recoveries of metal ions were determined in a single metal solution by the batch 
method in an excess of complexing agent (Papers II & III). After 24 h of agitation with a 
magnetic stirrer, the mixture was filtered and the final metal ion concentration was 
measured by a Zeenit 700 atomic absorption spectrometer (AAS). The recovery per cent of 
metal ion was calculated from the initial and final metal ion concentrations. Additional 
activated carbon (AC) supplement was used with the more water soluble compounds to 
enhance filtration and to bind any possible soluble metal complexes. AC addition took 
place 15 min after the addition of the complexing agent. The possible collection of unbound 
metal ions by AC was studied separately and taken into account when calculating the 
recoveries.  
3.7 PLANT GROWTH  
The seeds of an inbred accession of N. caerulescens Ganges (GA, also called St Laurent Le 
Minier) (Assunção et al. 2003) were sown in pots filled with 150 g of a mixture (1:4) of sand 
and Kekkilä Garden Soil for BPs 1b, 1d, 1e, 2a, 5a and 6 (Paper III). In addition, seeds were 
sown by first placing them in a sand-soil mixture and then the germinated seedlings were 
transferred to the pots containing 200 g of the sand-soil mixture including the sparingly 
soluble BP 1h at low and high concentrations. Other BPs and EDTA as a control were 
provided to the plants at low and high concentrations in different amounts of irrigation 
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water (10-100 ml) depending on their solubility. The metal ions, Cd2+, Ni2+, Zn2+ and Pb2+, 
were added in 10 ml of water as 3(CdSO4) × 8 H2O, NiSO4 × 6 H2O, ZnSO4 × 7 H2O and as 
Pb(NO3)2. Zero controls, BP controls (both low and high concentrations) and metal controls 
were included in the experiment. All the plants were grown in a greenhouse for seven 
weeks (winter time 5.11.12-15.1.13) after application of metals and BPs (18/20 °C night/day, 
18 h photoperiod, 200 μmol m-2 s-1) in Kuopio Finland (69.75° N, 5.34° E). 
3.8 THE GELATION PROCEDURE OF THE GEL-FORMING 
BISPHOSPHONATES  
The gelation of BPs was studied by first weighing the compounds (20-25 mg) in test tubes 
and adding the solvent (0.5 ml) (Paper IV). Next, the sample was sonicated for a few 
minutes and heated with a heat gun until the solid was dissolved or the boiling point of the 
solvent reached. The solution was left to cool at room temperature with a cap on. 
Observations with regard to the gelation were made after an hour by inverting the test 
tube. If the solid mass was immobilized, the material was defined as a gel. Xerogels were 
made by placing the hot solution on an evaporation dish, letting the gel form, and the 
solvent evaporate. The resulting solid was dried under vacuum.  
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4 Results and discussion 
In this section the main results are presented and discussed briefly. The detailed results and 
discussion can be found in the Papers I-IV. 
4.1 PHYSICOCHEMICAL PROPERTIES OF AMINOBISPHOSPHONATES 
(PAPER I) 
AminoBPs are an important class of molecules, since its members, such as pamidronate and 
alendronate are widely used in the clinic in the treatment of bone related diseases. Thus, it 
was necessary to investigate their physicochemical properties in detail under comparable 
conditions. A series of ten aminoBPs H2N(CH2)nC(OH)[P(O)(OH)2], in which n = 2-5, 7-11 
and 15 (compounds 1a-1j, Table 3) were synthesized as described in the General methods 
(3.1). Their aqueous solubilities, pKa values, thermal stability, liquid and solid state NMR 
as well as IR absorptions were determined. Two of the compounds, 1f and 1h, included one 
crystal water each based on the traditional elemental analysis and the results were verified 
by thermal decomposition analysis.  
The solubilities of the compounds were decreased as the length of the alkyl chain 
increased, as was expected (Figure 9, Table 1 in Paper 1). The compound with the shortest 
alkyl chain (1a) was crystallized as a monosodium salt, which presumably increased its 
solubility compared to the acidic form. Generally, compounds with shorter alkyl chains 1a-
1f were soluble in gram quantities, 1g in quantities of hundreds of milligrams and the last 
compounds (1h-1j) only tens of milligrams per liter. The reason for the poor solubility of 
the long alkyl chain compounds is most probably due to the increased hydrophobicity and 
the fact that the van der Waals forces of the alkyl chain overcome the hydrogen bonding 
forces between water and the heteroatoms of aminoBPs. The effect of the temperature was 
studied for selected compounds (1b, 1d, 1e) and the solubility was noted almost to double 
when increased from 7.6 ° to 50 °C (Figure 2 in Paper I). However, pH had only a minimal 
effect on the solubility of the compounds 1b, 1d and 1f while longer alkyl chain compounds 
1h and 1i displayed their lowest solubility at pH 2 with the values increasing at both lower 
and elevated pHs (Figure 3 in Paper I). 
 
  
Figure 9. The effect of the length of the alkyl chain of aminobisphosphonates on their aqueous 
solubility at 21 °C. 
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The pKa values were determined only for the first five compounds (1a-1e) because of the 
low solubility of the longer alkyl chain BPs (Table 2 in Paper I). The lengthening of the alkyl 
chain was shown to decrease the value of the last dissociation constant (pKa5, amino group) 
and increase the values of the other dissociation constants, in most cases. The first, pKa1 
values had larger error limits in comparison to other constants and they should only be 
considered as approximate values. In the cases of pamidronate (1a), alendronate (1b) and 
neridronate (1d), the measured values were compared to those found in the literature 
(Boichenko et al. 2009, Dyba et al. 1996, Hägele et al. 2000, Kubíček et al. 2007, Martell & 
Smith 2003, Yates & Rodan 1998, Zeevaart et al. 1999) (Tables 3 and 4 in Paper I), and were 
found to be in agreement when the different experimental conditions (e.g., background 
electrolyte, ionic strength, temperature or method used) were taken into account. 
4.2 CR(III) REMOVAL FROM AQUEOUS SOLUTIONS BY USING SOLID 
BISPHOSPHONATES (PAPER II) 
Chromium is generally known as a highly toxic pollutant metal which occurs in nature in 
its most stable oxidation states, trivalent and hexavalent forms (Mukherjee et al. 2013). 
Cr(VI) is the more toxic of these two forms but also Cr(III), which is an essential dietary 
element, has been shown to be a potential hazard, since its accumulation in living 
organisms can inhibit the enzyme systems (Aggarwal, Goyal & Bansal 1999, Anirudhan & 
Radhakrishnan 2007, Dahbi et al. 2002, Kanagaraj, Chandra Babu & Mandal 2008). 
Chromium effluents are generated widely in industry, e.g. in leather tanning. Thus, in 
order to prevent environmental pollution, the levels of chromium in the waste water are 
required to be reduced to very low concentrations (Aggarwal, Goyal & Bansal 1999, Aroua, 
Zuki & Sulaiman 2007). Consequently, novel, cost effective, rapid and straightforward 
methods are needed for Cr extraction.  
4.2.1 Metal chelation and solubility of a series of bisphosphonates 
Five classes of BPs with variable functional groups in R1 and R2 positions, a total of 16 
compounds (1g-1i, 2b-2e, 3a-3c, 4a-4b, 5b, 5c, 5e, 5g) (Table 3, chapter 3.1), were 
synthesized and their aqueous solubility and metal chelation with Cr3+, Fe3+, Ni2+ and Cu2+ 
tested. The solubilities of the compounds possessing shorter alkyl chain length were lower 
and the presence of the amino group either in the R1 or R2 position decreased solubility as 
compared to the other compounds due to zwitterion formation (Table 1 in Paper II). The 
BPs with short alkyl chain length (2b-c, 3a-b, 5b) or a Ph-group at the end of the alkyl chain 
(3a-c) did not exhibit optimal properties for metal chelation (Table 1 in Paper II). Two 
compounds with long alkyl chains 5g and 1h, the latter having an amino group at the end 
of the chain, displayed the best Cr3+ recoveries; 92 and 97%, respectively. Both of the 
compounds were extremely sparingly soluble in water and thus were examined in greater 
detail for their Cr3+ removal properties. 
4.2.2 Cr3+ recovery by compounds 5g and 1h as a function of pH 
Compounds 5g and 1h were fine microcrystalline powders that remained almost 
undissolved in the water solution during the metal chelation process and thus could be 
filtered subsequently without any additional precipitation step. As a comparison, the 
commercially available Diphonix® resin (Chiarizia et al. 1997) (Figure 7) was included in the 
study. The Cr3+ recovery was determined for the three compounds as a function of pH, 
since the pH can affect the protonation state of the BPs and play an important role in 
complex formation (Figure 5 in Paper II). Diphonix® and 5g were able to collect Cr3+ at 
acidic pH unlike 1h, which started to bind Cr3+ only at a pH value of about 3. On the other 
hand, 1h was able to collect Cr3+ also at pH 10 and above where 5g was not capable of 
binding the metal ions. Both of the BPs bound Cr3+ effectively in neutral and slightly basic 
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conditions, in contrast to Diphonix® with which the recovery was highest in acidic solution 
and decreased slowly as the pH increased. Not only the form of BPs but also the form of Cr 
changes at different pHs i.e. changing from the trivalent Cr3+ through divalent [Cr(OH)]2+ 
and monovalent [Cr(OH)2]+ forms to the neutral species Cr(OH)3(aq) and finally to the 
anionic species [Cr(OH)4]- (Aroua, Zuki & Sulaiman 2007, Kumar, Ray & Chakraborty 
2009). Chromium(VI), on the other hand, exists mostly in the anionic form throughout the 
pH range. Consequently, 5g and 1h were not able to chelate Cr(VI) efficiently and this 
property could be utilized in the separation of the two Cr species, Cr(III) and Cr(VI). 
4.2.3 Cr3+ removal from the waste water samples from the tannery industry 
The two BPs and Diphonix® were tested for their abilities to remove Cr3+ from waste water 
samples obtained from four tanneries. Compound 5g achieved clearly the best Cr3+ 
recoveries, mostly over 96%, being superior to 1h (Figure 10, Table 4 in Paper II). Diphonix® 
was the weakest of the compounds in its Cr3+ chelating properties even though it was also 
rather effective. The capacity for Cr3+ complexing of the most effective chelator, 5g, was 
significantly better (41.9 mg/g) than that of 1h (4.9 mg/g). The capacity of Diphonix® was 
also lower than by 5g, being 22.8 mg/g. Furthermore, a highly important factor in the 
processing of waste water, the regeneration of the chelating agents was investigated. Both 
of the BPs were observed to be regenerable at least seven times by using 2.0 M HCl solution 
with only a minor loss of the chelating agents during the process. 
 
  
Figure 10. Cr3+ recovery from four tannery effluents (Samples 1-4) by 1h, 5g and Diphonix® 
4.3 THE EFFECTS OF BPS ON THE PLANT GROWTH AND METAL REMOVAL 
FROM SOIL BY A HYPERACCUMULATIVE PLANT NOCCAEA 
CAERULESCENS (PAPER III) 
Trace elements originating from anthropogenic activity such as mine tailings, use of 
fertilizers and pesticides, industrial discharge etc., are one of the main pollutants in soil and 
currently a cause of public concern. Phytoremediation, which refers to the use of plants and 
associated microorganisms to remove pollutants from soil or to make them harmless, is 
both an ecological and economical way to remove harmful contaminants. Phytoextracting 
plants can remove metal(loid)s from soil by concentrating them in their harvestable parts. 
However, there are certain requirements for the characteristics of the plant to be used in 
phytoextraction: the ideal plant should be able to take up metal ions effectively from soil 
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into the root cells, load the metal ions into xylem and transport the metal ions from the 
roots to the shoots. (Ali, Khan & Sajad 2013, Vamerali, Bandiera & Mosca 2010, van der Ent 
et al. 2013, Vangronsveld et al. 2009) In the leaves, metal ions are stored within the cells and 
detoxified effectively (Meyer & Verbruggen 2012). 
Noccaea caerulescens is a well-studied plant, which can hyperaccumulate Zn(II), Cd(II) 
and Ni(II). Unfortunately, the plant has a low biomass and a slow growth rate and these are 
characteristics which virtually exclude the possibility of using this plant in the field for 
phytoextraction. (Bhargava et al. 2012, McGrath et al. 2006, Vangronsveld et al. 2009) 
Generally, the increase of the biomass of plants can be accomplished by using fertilizers. 
However, there is a report that N, P and S fertilization is not able to affect to any major 
extent the shoot biomass of N. caerulescens (Sirguey, Schwartz & Morel 2006). Furthermore, 
the possibility of adding chelating agents into the soil to improve metal bioavailability, 
uptake and translocation has been extensively studied, with EDTA being the most 
commonly used chelator due to its high efficiency in extracting several metal ions 
(Vamerali, Bandiera & Mosca 2010). However, EDTA is poorly biodegradable, it can be 
toxic to both the plants themselves as well as to soil microbial communities, and it poses the 
risk of metal leaching (Grčman et al. 2001).  
The concept of treating N. caerulescens with BPs was to determine whether the metal 
chelation properties of BPs could be exploited to enhance the metal solubility in the soil, 
root uptake and shoot metal removal and to prevent the negative effects of the contaminant 
metal ions on the plant growth and the rhizosphere. Thus, the single addition of seven BPs 
(1b, 1d, 1e, 1h, 2a, 5a and 6, Table 3) and EDTA into the soil and the influence of these 
compounds on shoot yield as well as on metal concentration and removal by N. caerulescens 
Ganges ecotype was investigated in a pot experiment. The metals studied were Cd(II), 
Ni(II), Zn(II) and Pb(II), and the plants were grown in clean and metal spiked soils in order 
to compare the efficiency of the treatments. 
4.3.1 Plant growth 
The treatment with low concentrations of BPs 1b, 1d, 1e, 1h, 2a, 5a and 6 increased the 
shoot yield (FW) slightly compared to the zero control; however, the differences were not 
statistically significant (Figure 11, Table 1 in Paper III). The reference compound EDTA, had 
opposite effects on the plant growth and the shoot yield was numerically lower than that of 
the control (although not statistically significant). The treatment with a low concentration of 
1h produced a high shoot yield as compared to the zero control (Figure 11, Table 2 in Paper 
III). On the other hand, treatments with high concentrations of BPs decreased the shoot 
yield except for compound 1h, with which the shoot yield remained at the same level as 
found with the control. Plants did not tolerate the treatment with a high EDTA 
concentration and died, probably due to the binding of vital metals, such as Fe and Zn, and 
the induction of physical disorders by the excess EDTA (McGrath et al. 2006). The 
treatment with Cd (low concentration) did not affect the shoot yield in any significant 
manner (Figure 11, Tables 1 and 2 in Paper III). However, it restored the shoot yield of 
EDTA-treated plants, which was very low without the Cd addition, back to the control 
level. Similarly, Zn and Pb (high concentrations) additions did not have any significant 
effects on the plant growth compared to the plants treated with high concentrations of BPs 
(Tables 1 and 2 in Paper III). 
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Figure 11. The shoot fresh weight of N. caerulescens treated with bisphosphonates and EDTA in 
clean, Cd- and Ni-spiked soil (n = 3); a) Concentration for 1b, 1d, 1e, 2a, 5a, 6 and EDTA 
0.25 mmol/kg soil DW; Cd and Ni 0.05 mmol/kg soil DW; b) Concentration for 1h 0.21 
mmol/kg soil DW; Cd 0.029 and Ni 0.075 mmol/kg soil DW. 
 
Ni treatment, on the other hand was harmful to the plants since the shoot yields declined 
as compared to those resulting from the treatment solely with low concentrations of BPs 
(Figure 11, Table 1 in Paper III). However, surprisingly compound 1h managed to maintain 
the shoot yield of the plant as high as in the treatment without Ni. In addition, the shoot 
FW yield was considerably higher for 1h + Ni plants than for any of the other Ni plants. It is 
difficult to provide an explanation for this effect induced by BP 1h because of the 
complicated plant metabolism involved and the possible enzyme inhibition caused by BPs. 
In previous studies it was shown that compound 1h was an effective metal chelator (Paper 
II). The major difference between sparingly soluble 1h with the other compounds in the 
experiment, i.e. water soluble BPs, was its composition in a solid, microcrystalline form in 
the soil and its ability to form stable, insoluble metal complexes. This suggests that the 
enhancement of the growth of Ni treated plants by 1h would be attributable to the metal 
chelation in the soil. Nevertheless, the mechanism of the increase of shoot yield by 1h 
clearly demands further investigation.  
4.3.2 Shoot metal concentrations and metal removal from soil 
The shoot metal concentrations of N. caerulescens were not significantly affected by the BP 
treatments (Tables 3 and 4 in Paper III). Only compound 1e was able to increase the Pb 
concentration in clean soil compared to the control. Generally, in the metal spiked soils, the 
shoot Cd concentration was about 600 μg/g DW and the Zn concentration about 5000 μg/g 
DW, which both exceed the limit required for a hyperaccumulative plant (van der Ent et al. 
2013). The Pb concentrations were generally under 50 μg/g DW and the Ni concentrations 
varied extensively, the values ranging from around 240 down to 20 μg/g DW. 
However, in view of the practical applications of phytoextraction, it is essential to take 
into account the dry weights of the plants to calculate the shoot metal removal so that one 
can determine the amount of metals that could be removed from soil. Consequently, 
differences occurred in shoot metal removal arising from the high shoot yields of plants 
treated with 1h. Firstly, the shoot Pb removal in clean soil was enhanced, as was shoot Zn 
removal in Zn-spiked soil. However, most importantly, the shoot Ni removal in Ni-spiked 
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soil was clearly better with the plants treated with 1h. In an attempt to clarify the potential 
of 1h in practical use of Ni removal from soil, the next experiments should be conducted in 
real contaminated soils containing several metals and other contaminants which might 
interfere with its properties of shoot metal removal.  
4.4 NOVEL BISPHOSPHONATE GELATORS (PAPER IV) 
Gels forming in aqueous solutions, i.e. hydrogels are generally rather applicable for 
biomedical and pharmaceutical purposes attributed to their biodegradability and 
resemblance of natural living tissue due to their high water content. Thus, there are many 
possible applications of hydrogels e.g. in tissue engineering and drug delivery. (Peppas et 
al. 2000) In this study, the first BP gelators, three compounds (5d-5f, Table 3) forming 
hydrogels and one (7) an organogel were discovered. The general properties of BPs, such as 
the high affinity for bone as well as their non-toxicity, might provide new insights into the 
use of BP hydrogels. After the discovery of the new BP gelators, it was essential to analyze 
the structures of the formed gels. Thus, a wide selection of analytical tools (solid state 13C 
and 31P cross polarization magic angle spinning (CPMAS) and solution state NMR 
spectroscopy, IR spectroscopy, powder X-ray diffraction (XRD), thermal analysis and 
scanning electron microscopy (SEM)) were used to clarify the structures and properties of 
the gels.   
4.4.1 Gel formation by bisphosphonates  
Compound 5d formed a 4% (w/v) transparent non-flowing gel in water, whereas for 
compounds 5e and 5f the concentration of the non-flowing gels were 5% (w/v), the first 
appearing transparent whereas the latter was turbid (Table 1 in Paper IV). Compound 7 
needed a mixture of two organic solvents for gel formation. The solid was first dissolved in 
methanol, after which 2-propanol, acetone, or ether was added forming a 5% (w/v) yellow 
gel.  
4.4.2 Solution state NMR spectroscopy 
The thermal stability of the gels 5d-5f was studied by using variable-temperature 1H NMR 
measurements. The spectra were recorded in 5 °C steps between temperatures of 30 - 95 °C 
(Figures 2-4 in Paper IV). Gel 7 could not be heated because this caused the evaporation of 
the organic solvents. At lower temperatures, the signals appeared very broad and only 
those with highest intensities were visible. For gels 5d and 5f from temperatures of 50 °C 
and 80 °C, respectively upwards the signals started to become sharper step by step and the 
coupling pattern gradually became more resolved. This reflects the change of the sample 
from a viscoelastic gel to a more and more liquid form suggesting that these gels do not 
have explicit melting temperatures; instead they change phases rather gradually. However, 
for gel 5e, the change observed was more distinct, since the broad signals appeared as 
dramatically narrower at 75 °C, indicating that the gel had transformed to the sol between 
70 and 75 °C. Moreover, the water signal narrowed at the temperature  75 C, which was 
not seen in the spectra of compounds 5d and 5f, suggesting that the water molecules are an 
essential part of this gel assembly. The different behavior of the water signal was also 
observed in the concentration dependent 1H NMR spectra (1 - 5% w/v) of gel 5e (Figure S3 
in ESI of Paper IV). Thus, the intensity of the water signal decreased significantly at the 
concentration of  4%, whereas for compounds 5d and 5f the intensity remained about the 
same at every concentration. This probably indicates that the exchange of water molecules 
between the gel and the sol state is restricted in the case of compound 5e, thus supporting 
the previous proposal according to which the water molecules are more tightly bound 
within the 5e gel network when compared with gels formed by 5d and 5f. In addition, the 
concentration dependent spectra exhibited a clear broadening of the signal width at 
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concentrations of  3% for compounds 5d and 5f, and at  4% for compound 5e indicating 
an increase in viscosity of the samples by increase of the concentration, most probably due 
to restrictions in the free tumbling of the gelator molecules (Figures S2-S4 in ESI of Paper 
IV). 
4.4.3 Solid state NMR spectroscopy 
13C and 31P solid state NMR spectra were recorded for the bulk synthesis products, xerogels, 
and hydrogels (Figures 5-8 in Paper IV). The 13C CPMAS spectra of the synthesis products 
of 5d-5f resembled closely those of the hydrogels. However, the spectra of the xerogels 
were slightly different from the other spectra with new signals appearing in the area of 
alkyl chain signals (around 20 to 35 ppm) indicative of some changes in the alkyl chain 
assembly or conformations. Again, the spectrum of hydrogel 5e was dissimilar from the 
hydrogels of 5d and 5f showing clearly wider and more unclear signals. This observation 
supports the proposal that water molecules play an essential role in the gel assembly since 
the wide signals appear for many structures closely resembling each other.  
In the 31P CPMAS spectra of the synthesis products 5d-5f, the signals exhibited the same 
chemical shift at around 24.8 ppm (Figure 9: 1-3 in Paper IV). The signal, however, had 
clearly become divided into two for compound 5d, whereas for 5f its shape was as if the 
two signals had merged together and in the spectrum of compound 5e, the phosphorus 
gave rise to a single signal. Since 13C CPMAS spectra possessed a singlet peak for each 
carbon, the origin of doubled structure of 31P CPMAS spectra of 5d and 5f was probably 
due to the nonequivalence of two phosphorus nuclei whereas in 5e, the chemical shift 
difference was so small that it was not resolved. Based on 13C CPMAS spectra, there was 
only one molecule in an asymmetric unit in the crystals of the synthesis products and 
xerogels of 5d-5f. In the 31P CPMAS spectra, the xerogels of 5d-5f behaved similarly to each 
other and two new signals compared to the spectra of synthesis products were observed 
(Figure 9 in Paper IV). The 31P CPMAS spectra of the hydrogels 5d and 5f were very similar, 
having one signal at around 24 ppm, but in the spectrum of hydrogel 5e, this peak was 
wider and deformed. 
4.4.4 Structural properties by X-ray diffraction  
The synthesis products and xerogels of 5d-5f produced perceptibly similar XRD patterns 
which indicated moderate crystallinity of the samples (Figure 11 in Paper IV). Generally, an 
increase in aliphatic chain length could induce a one-dimensional change of the unit cell, 
since the long aliphatic chain favors a parallel packing motif due to the repetitive van der 
Waals interactions that are gradually enhanced by an increase in the alkyl chain length 
(Boczula et al. 2012, Gbabode et al. 2006, Moreno-Calvo et al. 2009, Peuronen et al. 2012, 
Zuniga & Chapuis 1983). Thus, this packing mechanism along with the capability to form 
hydrogen bonds between the phosphonic acid groups (and/or with solvent molecules; 
water in this case) are presumably the prevailing packing forces that most likely guide the 
structures to form parallel-packed structure modifications, which in part may have 
contributed to the relatively high crystallinity of the synthesis products and the 
corresponding xerogels of compounds 5d-5f. Compound 7 and its corresponding xerogel, 
on the other hand, were poorly crystalline, which meant that their structural characteristics 
remained somewhat unclear. 
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5 Conclusions and future perspectives 
In this thesis, novel applications related to BPs were discovered and investigated. The 
utilization of the metal chelation properties of BPs in the waste water purification as well as 
in the removal of metals from the soil by using a hyperaccumulative plant was 
investigated. In addition, a completely novel characteristic of BPs, the formation of organo- 
and hydrogels was discovered. 
The purification of waste waters containing harmful metal ions is a current topic 
constantly discussed in the media. The protection of the environment from metals 
originating from mining and industry is a topic attracting more and more attention. It does 
seem that the purification methods currently available (Mukherjee et al. 2013), such as 
precipitation (Esmaeili, Mesdaghi & Vazirinejad 2005, Fabiani et al. 1997, Hintermeyer et al. 
2008, Inglezakis, Loizidou & Grigoropoulou 2003, Kanagaraj, Chandra Babu & Mandal 
2008, Mohan & Pittman Jr 2006, Wu et al. 2008), ion/exchange (Anirudhan & Radhakrishnan 
2007, Cetin et al. 2012, Liu et al. 2001, Sahu et al. 2009), adsorption (Dahbi et al. 2002, Fahim 
et al. 2006, Fathima, Raghava & Nair 2012, Mahmoud et al. 2010, Mohan, Singh & Singh 
2006, Rivera-Utrilla & Sanchez-Polo 2003, Tahir & Naseem 2007) and membrane processes 
(Barakat & Schmidt 2010, Fabiani et al. 1997, Gomes et al. 2010, Hintermeyer et al. 2008, 
Religa, Kowalik & Gierycz 2011) do not meet well enough the needs of industry. The novel 
method presented in this thesis using sparingly soluble BP for Cr3+ removal confers several 
benefits compared to the methods currently in use. Firstly, there is no need to use any extra 
material, such as resin, during the process, and the solid BP is readily filterable from the 
solution after the metal chelation. In addition, it lacks the need for a precipitation step 
which is mandatory for soluble chelating agents. Moreover, the production costs are low: 
the syntheses of the BPs are straightforward with good yields and they are based on 
inexpensive starting materials. The regenerability of these compounds also diminishes the 
operation costs. Another advantage of these compounds is the wide pH range of efficient 
complexation of Cr3+. However, to further improve the usability of BPs in general in waste 
water purification, they could be conjugated to porous silicon material which has a large 
surface area leading to the maximal metal collection capacity of the material. In addition, a 
hybrid material of this kind would be better suitable for flow-through systems.  
The discovery of the Cr3+ selective BP encourages for the search of other metal selective 
BPs to be utilized in this manner. First of all, the mechanism of this adsorbtion reaction 
would be worthwhile clarifying in the future e.g. by using single crystal and powder XRD, 
surface area measurements, SEM, transmission electron microscopy (TEM) and zeta 
potential. In addition, molecular modeling could be exploited for understanding the metal 
chelation process. However, the large size of the ligands forming the system might make 
the task challenging. Based on the studies related to this thesis, the long alkyl chain as a 
substituent in the BP structure is a favorable characteristic concerning both the metal 
chelation as well as the low solubility required for applicability. On the other hand, the 
presence of a phenyl group as the substituent was not beneficial for the metal binding. 
These relationships between the structure and the affinity for metal ions could be 
elucidated in the future by preparing new classes of BP structures and testing their metal 
chelation abilities for different groups of metal ions with variable oxidation states, starting 
from the transition elements, such as Mn(II), Cu(I)/(II), Zn(II), Co(II) and Ni(II). 
Furthermore, the divergent behavior of the BP ligands in metal chelation regarding pH, 
temperature and contact time could be utilized for the selective recovery of the metal ions. 
Another group of interest for selective chelators would be the rare earth elements, such as 
Sc(III), Eu(III), Y(III) and La(III) for which the extraction from the ore is challenging and 
requires novel methods.  
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Despite the extensive research in the field of herbicidal activity of BPs, the other 
beneficial properties of BPs, such as metal chelation, have not been previously considered 
to be utilized with plants. Phytoremediation, the use of plants to remove pollutants or make 
them harmless in soil, is a putative solution for the ever-increasing problems originating 
from water and soil contamination. Metal chelators, such as EDTA have been added into 
the soil in order to achieve increasing metal bioavailability, better uptake and improved 
translocation. (Ali, Khan & Sajad 2013, Vamerali, Bandiera & Mosca 2010, van der Ent et al. 
2013, Vangronsveld et al. 2009) Thus, it was of interest to find out if BPs could act in the 
same way as effective metal chelators. Nonetheless, in our experiments, BPs did not 
increase the metal concentration in N. caerulescens. However, another beneficial effect was 
observed: by treatment with a sparingly soluble aminoBP which had a long alkyl chain in 
its structure (1h, see Table 3) the shoot biomass of the plant was increased, especially in the 
Ni-spiked soil thus, enhancing the shoot Ni removal from the soil. Since BPs have not been 
noted previously to have such an impact, it would be important to resolve the mechanism 
of this phenomenon. Firstly, the possible mode of transfer of the solid BP to the roots of the 
plant from the soil and further from roots to shoots needs to be clarified, for example by 
using a mass spectrometric method. In addition, the effects of the BP on FPPS expression 
could be investigated by molecular biological methods. The possible practical application of 
the elevated Ni removal by BP could be the purification of Ni contaminated soils. Hence, 
the efficacy of the method should be verified in Ni rich soil derived from Ni contaminated 
areas.    
The discovery of BP gelator compounds especially in the case of hydrogelators can be 
considered of as a major advance, taking into account the importance of BPs in medicine 
and pharmacy. The chemical and physical nature of the formed gels were investigated 
using several analytical techniques, including liquid and solid state NMR and IR 
spectroscopy, scanning electron microscopy, powder X-ray diffraction, and thermal 
analysis. A detailed picture of the solid state structures of the synthesis products as well as 
the corresponding xerogels were drawn together with the thermal degradation and 
hydration levels of the compounds. The results showed that water plays an important role 
in the hydrogels formed by compounds 5d-5f (Table 3), however the function of the water 
was different in the case of compound 5e, in which the water molecules are more tightly 
bound within the gel network. The long alkyl chains combined with the ability of the 
phosphonate groups to form hydrogen bonds most likely guide the structures to form 
parallel-packed structure modifications, contributing to the high crystallinity found in 
compounds 5d-5f and their xerogels, which also showed potential liquid crystal properties. 
In the future, to study the suitability of the gels for different purposes e.g. drug delivery 
related applications, the stability of the gel composition with additional substances (drug) 
and the release of drug from the gel will need to be tested. 
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6 Summary 
The core of this thesis is summarized in Figure 12 where the central applications of BPs 
mentioned in the literature review as well as the novel applications developed in this study 
(Papers II-IV) are presented. The medical applications in the blue frames still clearly 
dominate the picture. However, the new applications related to this work (outlined in 
green) are on the other side with the non-medical applications, with hydrogelators placed 
in the middle for their still unknown possible uses. The location of the new applications 
highlights the versatility of BPs: Even though these compounds have been studied for 
decades, there is still a huge potential for their exploitation in different areas for 
revolutionary inventions to be made in the future. 
 
 
 
Figure 12. Summary of applications related to bisphosphonates 
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Bisphosphonates are chemicals 
suitable for various applications, 
mostly related to their ability to 
prevent bone resorption, and are 
used e.g. as drugs for osteoporosis 
and Paget’s disease. They possess 
also other useful characteristics, 
including effective metal chelation, 
anticancer, antiparasitic and anti-
inflammatory properties as well 
as herbicidal effects. This study 
reveals three new bisphosphonate 
related applications highlighting new 
possibilities for utilizing BPs in the 
future in waste water treatment, soil 
purification and as hydrogelators. 
